



UNIVERSITI PUTRA MALAYSIA

***ETHNOBOTANICAL STUDY OF ANTICANCER PLANTS USED IN
UGBINE, NIGERIA AND BIOACTIVITY-GUIDED ISOLATION OF
CYTOTOXIC AGENTS FROM *Synclisia scabrida* (Miers) ex Oliv***

NWAEFULU OGOCHUKWU NGOZI

FPSK(p) 2022 26



**ETHNOBOTANICAL STUDY OF ANTICANCER PLANTS USED IN UGBINE,
NIGERIA AND BIOACTIVITY-GUIDED ISOLATION OF CYTOTOXIC
AGENTS FROM *Synclisia scabrida* (Miers) ex Oliv**

By

NWAEFULU OGUCHUKWU NGOZI

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfilment of the Requirements for the Degree of Doctor of Philosophy**

June 2022

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia

DEDICATION

This work is dedicated to God Almighty; the source of life, all wisdom and knowledge for His immeasurable love and favour towards me.



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of
the requirement for the degree of Doctor of Philosophy

**ETHNOBOTANICAL STUDY OF ANTICANCER PLANTS USED IN UGBINE,
NIGERIA AND BIOACTIVITY-GUIDED ISOLATION OF CYTOTOXIC
AGENTS FROM *Synclisia scabrida* (Miers) ex Oliv**

By

NWAEFULU OGOCHUKWU NGOZI

June 2022

Chairman : Professor Johnson Stanslas, PhD
Faculty : Medicine and Health Sciences

Introduction: Plants are promising source of novel anticancer agents. Although many breakthroughs have been made in cancer treatment, it remains suboptimal. Therefore, alternative therapeutics with novel mechanisms of action, with minimal side effects and costs are urgently needed.

Method: Structured questionnaires were used for the ethnobotanical study. The ground whole roots and leaves of *Synclisia scabrida* (Miers) ex Oliv (SS) and leaves of *Petiveria alliacea* L. (PA) were sequentially and separately extracted using a solid–solvent ratio of 1:2, of hexane, dichloromethane, ethyl acetate, methanol, or dichloromethane: methanol (1:1), by cold maceration for 72 h followed by another cold maceration for 24 h. The extract was filtered, concentrated at 40°C with a rotary evaporator and further dried in the oven set at 40°C to obtain crude extracts, which were stored in a refrigerator. A preliminary phytochemical analysis of SS whole root methanol extract was carried out. MTT cell viability assay was employed to evaluate the cytotoxicity potential of the extracts/compounds in colon (HCT-116), prostate (PC-3), breast (MCF-7), pancreatic (PANC-1) cancer cells and human normal lung (BEAS-2B) and murine microglial (BV-2) cells. Cell cycle distribution of treated PANC-1 was analysed by flow cytometry for understanding of the mechanism behind the observed anticancer potential of SS. Using a bioassay-guided approach, the most active extract/fraction were purified to yield 4 active compounds (SS_C1, SS_C2, SS_C3 and SS_C4). The structures of SS_C2 and SS_C4 were successfully characterised using ¹H, ¹³C-NMR, COSY, HMBC, HSQC, FTIR and LC/MS Q-TOF spectroscopy. The compounds' molecular targets were predicted using *in silico* molecular docking and molecular dynamic approaches.

Results: The ethnobotanical study revealed the use of SS and PA for cancer treatment. Phytochemical screening of the methanol extract confirmed the presence of alkaloids, tannins, flavonoids, steroids, and fixed oil. The methanol extract had the following IC₅₀

($\mu\text{g/mL}$) in cancer cell lines: HCT-116 (23.3 ± 10.4), MCF-7 (35.0 ± 5.0), PC-3 (29.3 ± 11.0) and PANC-1 (5.7 ± 1.2). SS induced a dose-dependent arrest of PANC-1 cells in the S phase. Structure elucidation of SS_C2 and SS_C4 revealed they are bisbenzylisoquinoline alkaloids. Both compounds were identified as close analogues of cosculine and cycleanine, respectively. SS_C2 ($\text{IC}_{50} = 46.7 \pm 5.8 \mu\text{g/mL}$; SI = 2.1; $P < 0.000$) and SS_C4 ($\text{IC}_{50} = 41.7 \pm 7.6 \mu\text{g/mL}$; SI = 2.4; $P < 0.000$) were selectively toxic towards HCT-116 and MCF-7, respectively. The selectivity was far greater than that of gemcitabine, which showed higher toxicity to normal lung cells (BEAS-2B). The *in silico* molecular dynamic simulations results showed RMSF plots of PARP1-ligand complexes were more stable than the apo protein. This shows a very high PARP1-ligand complexation stability, suggesting that both ligands (SS_C2 and SS_C4) are potential PARP1 inhibitors.

Conclusion: SS_C1 was active against colon and pancreatic cancers, SS_C2 was selectively active against colon cancer while SS_C4 had the best selectivity towards breast cancer cells. SS_C2 and SS_C4 are new bisbenzylisoquinoline alkaloids, and potential PARP1 inhibitors which could become leads for the development of targeted therapy for the treatment of colon, breast, and pancreatic cancers.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai
memenuhi keperluan untuk ijazah Doktor Falsafah

**KAJIAN ETNOBOTANI TUMBUHAN ANTIKANSER YANG DIGUNAKAN DI
UGBINE, NIGERIA DAN PENGASINGAN BERPANDUKAN BIOAKTIVITI
EJEN-EJEN SITOTOSIK DARI *Synclisia scabrida* (Miers) ex Oliv**

Oleh

NWAEFULU OGOCHUKWU NGOZI

Jun 2022

Pengerusi : Profesor Johnson Stanslas, PhD
Fakulti : Perubatan dan Sains Kesihatan

Pengenalan: Tumbuhan merupakan sumber yang dipercayai mampu dijadikan sebagai agen antikanker baru. Meskipun banyak penemuan dalam rawatan kanser telah berjaya diperkenalkan, namun ia masih di tahap separa optimum. Oleh yang demikian, terapi alternatif bersama mekanisme tindakan baru, dengan kesan sampingan dan kos perbelanjaan yang minimum diperlukan segera.

Kaedah: Soal selidik berstruktur telah diguna pakai bagi tujuan kajian etnobotani. Setiap akar dan daun *Synclisia scabrida* (Miers) ex Oliv (SS) dan juga daun *Petiveria alliacea* L. (PA) diekstrak secara berasingan, mengikut turutan dengan menggunakan nisbah 1:2 bagi pepejal kepada pelarut heksana, diklorometana, etil asetats, metanol, atau diklorometana: metanol (1:1), dengan pemerasan sejuk selama 72 jam diikuti dengan pemerasan sejuk yang seterusnya selama 24 jam. Ekstrak ditapis, dipekatkan pada suhu 40°C dengan menggunakan penyejat berputar dan selanjutnya dikeringkan dalam ketuhar yang ditetapkan pada suhu 40°C untuk mendapatkan ekstrak mentah, yang kemudiannya disimpan di dalam peti sejuk. Analisis fitokimia awal bagi ekstrak metanol akar SS telah dijalankan. Analisis MTT viabiliti sel digunakan untuk menilai potensi sitotoksiti ekstrak/sebatian dalam sel kanser kolon (HCT-116), prostat (PC-3), payudara (MCF-7), pankreas (PANC-1) dan sel normal paru-paru manusia (BEAS-2B) dan sel mikroglial murin (BV-2). Taburan kitaran sel PANC-1 yang dirawat telah dianalisis menggunakan sitometri aliran untuk mengenalpasti mekanisme di sebalik potensi SS sebagai agen antikanker. Dengan menggunakan pendekatan yang berpandukan biocerakinan, ekstrak/pecahan yang paling aktif telah dimurnikan bagi menghasilkan 4 sebatian aktif (SS_C1, SS_C2, SS_C3 dan SS_C4). Struktur SS_C2 dan SS_C4 telah berjaya dicirikan menggunakan spektroskopi ^1H , $^{13}\text{C-NMR}$, COSY, HMBC, HSQC, FTIR dan LC/MS Q-TOF. Sasaran molekul sebatian telah diramalkan dengan menggunakan pengedokan molekul siliko dan beberapa pendekatan dinamik molekul.

Keputusan: Kajian etnobotani telah menunjukkan kegunaan SS dan PA dalam rawatan kanser. Pemeriksaan fitokimia ekstrak metanol telah mengesahkan kehadiran alkaloid, tanin, flavonoid, steroid, dan minyak lemak. Ekstrak metanol mempunyai IC₅₀ ($\mu\text{g/mL}$) yang berlainan terhadap setiap sel kanser yang berikut: HCT-116 (23.3 ± 10.4), MCF-7 (35.0 ± 5.0), PC-3 (29.3 ± 11.0) dan PANC-1 (5.7 ± 1.2 ; $P < 0.009$). SS telah membantutkan sel PANC-1 pada fasa S, dengan bergantung kepada dos. Penjelasan struktur SS_C2 dan SS_C4 telah mendedahkan bahawa ia adalah alkaloid bisbenzylisoquinoline. Kedua-dua sebatian telah dikenal pasti sebagai analog rapat cosculine dan cyclanine. Secara selektifnya, kesan toksik telah diperlihatkan oleh SS_C2 ($\text{IC}_{50} = 46.7 \pm 5.8 \mu\text{g/mL}$; SI = 2.1; $P < 0.000$) terhadap HCT-116 manakala SS_C4 ($\text{IC}_{50} = 41.7 \pm 7.6 \mu\text{g/mL}$; SI = 2.4; $P < 0.000$) terhadap MCF-7. Selektiviti tersebut adalah jauh lebih besar daripada gemcitabine, yang menunjukkan ketoksikan yang lebih tinggi kepada sel paru-paru normal (BEAS-2B). Keputusan simulasi dinamik molekul dalam siliko menunjukkan plot RMSF kompleks PARP1-ligan lebih stabil berbanding protein apo. Ini menunjukkan kestabilan kompleksasi PARP1-ligan yang sangat tinggi, seterusnya mencadangkan bahawa kedua-dua ligan (SS_C2 dan SS_C4) berpotensi sebagai perencat PARP1.

Kesimpulan: SS_C1 aktif terhadap kanser kolon dan pankreas, SS_C2 aktif secara selektif terhadap kanser kolon manakala SS_C4 mempunyai selektiviti terbaik terhadap sel kanser payudara. SS_C2 dan SS_C4 ialah alkaloid bisbenzylisoquinoline baru dan berpotensi sebagai perencat PARP1 yang mampu menjadi peneraju untuk perkembangan terapi bersasar untuk rawatan kanser kolon, payudara dan pankreas.

ACKNOWLEDGEMENTS

This PhD journey was practically impossible until the Almighty God arose and became the initiator and the administrator Himself. Even without any government funding, He sponsored me in a foreign university. All praise, glory and honour to Him, the creator of the Heavens and the Earth.

Special thanks to my supervisor, Prof. Dr. Johnson Stanslas for his guidance and support; your wise advice helped to direct my course. My gratitude also goes to all members of my supervisory committee for finding time to read through and made useful contributions towards my thesis. Worthy to mention your name, Dr. Mohammad Kaisarul Islam, I say you were God-sent. Although you were not part of the supervisory committee, but you came to our lab the time you were needed most and contributed a lot towards the isolation of my compounds. Dr Nizar Al-Shar'I contributed to running the molecular dynamics simulation of my compounds, I appreciate your effort Sir.

Many thanks to University Putra Malaysia, for awarding me International Graduate Student Scholarship (IGSS). I would also want to thank my lab mates and my friends especially Yuan Han Teh, Khor Poh Yen, Quah Shun Ying, Ibrahim Badamasi and Amir Imran; each of you encouraged me in your own ways. Ahmad Badawi single-handedly formatted my thesis without any charge, you are appreciated.

Drs Edwin Ekweaga and Nelson Obata, you are friends indeed. You have not only encouraged me but had answered my call for financial assistance. Prof (Mrs) Josephine Owolabi, you were not only my co-supervisor but had been a catalyst in this whole process of coming to Malaysia for this programme. Prof & Mrs Ugo Ugorji and Rev. canon Uche Iwuozor stood in the place of prayers for me. Mr Samuel Oyebanji assisted in the ethnobotanical survey and plants collection. You all are appreciated.

My heart-felt gratitude goes to my ever-loving and caring parents (of the blessed memory), who desired the best for me, solidly stood behind me, prayed fervently and sacrificed a lot towards my PhD pursuit. Although you are no more to see the completion of that journey, your name is eternally engraved on my certificate, hence wherever and whenever it is used, you will be remembered. Keep resting in the bosom of the Lord until I see your face again.

Worthy to mention is the immeasurable financial support from my dearest brothers Tony, Ifeanyi and Benson. My sisters and other brothers encouraged me through their prayers and words of encouragement. Your labour of love will never go unrewarded.

To my daughter, thank you so much for your patience and resilience. You were left when you were less than 3 years, yet God kept you. Finally, the best thing that ever happened to me, the man whom God gave to me as my husband, Pst. Chuks Nwaefulu. You are

wonderful in your love, prayers, understanding and sacrifices you made to see me attain this height. Thanks for standing in for me when I was away and keeping your faith alive in God. Severally, when it seemed I could not continue, you encouraged, prayed, and cheered me up. Your reward shall be great in Jesus' name. Amen. I love you!

My sincere gratitude to everyone, although not individually named here, who had contributed directly or indirectly to the success of my thesis.

This thesis was submitted to the Senate of the Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Johnson a/l Stanslas, PhD

Professor

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Chairman)

Lim Chee Woei, PhD

Senior Lecturer

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Member)

Omonkhelin Josephine Owolabi, PhD

Professor

Pharmacology and Toxicology

University of Benin, Nigeria

(Member)

Lam Kok Wai, PhD

Associate Professor

Faculty of Pharmacy

University Kebangsaan Malaysia

(Member)

Sreenivasa Rao Sagineedu, PhD

Senior Lecturer

Department of Pharmaceutical Chemistry

International Medical University

(Member)

ZALILAH MOHD SHARIFF, PhD

Professor and Dean

School of Graduate Studies

Universiti Putra Malaysia

Date: 10 November 2022

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature:

Name of Chairman
of Supervisory
Committee:

Professor Dr. Johnson a/l Stanslas

Signature:

Name of Member
of Supervisory
Committee:

Dr. Lim Chee Woei

Signature:

Name of Member
of Supervisory
Committee:

Professor Dr. Omonkhelin Josephine Owolabi

Signature:

Name of Member
of Supervisory
Committee:

Associate Professor Dr. Lam Kok Wai

Signature:

Name of Member
of Supervisory
Committee:

Dr. Sreenivasa Rao Sagineedu

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	iii
ACKNOWLEDGEMENTS	v
APPROVAL	vii
DECLARATION	ix
LIST OF TABLES	xvi
LIST OF FIGURES	xviii
LIST OF APPENDICES	xxiii
LIST OF ABBREVIATIONS	xxx
 CHAPTER	
1 INTRODUCTION	 1
1.1 Background of study	1
1.2 Statement of research problem	4
1.3 Hypotheses of study	4
1.4 General Objective	4
1.5 Specific Objectives	4
2 LITERATURE REVIEW	 5
2.1 Cancer	5
2.2 Toxicity of Cancer Chemotherapy	7
2.3 Herbal Medicine	8
2.4 Anticancer Drugs Derived from Plants	9
2.5 Natural Compounds with Anticancer Properties	9
2.5.1 Alkaloids	10
2.5.2 Flavonoids	12
2.5.3 Tannins	14
2.5.4 Saponins	14
2.6 Methods for the Discovery of Plant-Derived Natural Products	18
2.6.1 Extraction	18
2.6.1.1 Maceration	18
2.6.1.2 Infusion	19
2.6.1.3 Digestion	19
2.6.1.4 Percolation	19
2.6.1.5 Decoction	19
2.6.1.6 Soxhlet Extraction	19
2.6.2 Fractionation and Purification	21
2.6.2.1 Chromatographic Techniques	21
2.6.2.2 Thin Layer/Preparative Thin Layer Chromatography	21
2.6.2.3 Column Chromatography	22
2.6.2.4 Gas Chromatography	23

	2.6.2.5	High Performance Liquid Chromatography	24
	2.6.3	Bioassay-Guided Isolation of Medicinal Plants	24
	2.6.4	Structure Elucidation Techniques	26
	2.6.4.1	Mass Spectrometry	26
	2.6.4.2	Ultraviolet Spectroscopy	26
	2.6.4.3	Nuclear Magnetic Resonance Spectroscopy	26
2.7		Computational Chemistry	27
	2.7.1	Molecular Docking	27
	2.7.1.1	Scoring Function	27
	2.7.1.2	Applications of Molecular Docking	27
	2.7.2	Molecular Dynamics (MD) Simulation	28
	2.7.2.1	Conventional MD Simulations	28
	2.7.2.2	MD in Drug Discovery	28
2.8		<i>Synclisia scabrida</i> (Miers) ex Oliv	28
	2.8.1	Ethnobotanical Uses of <i>S. scabrida</i>	29
	2.8.2	Reported Phytochemicals/Compounds in <i>S. scabrida</i>	29
	2.8.3	Pharmacological Properties of <i>S. scabrida</i>	31
2.9		<i>Petiveria alliacea</i> Linnaeus	31
	2.9.1	Ethnobotanical Uses of <i>P. alliacea</i>	32
	2.9.2	Pharmacological Properties of <i>P. alliacea</i>	32
	2.9.3	Reported Phytochemicals in <i>P. alliacea</i>	32
3		ETHNOBOTANICAL SURVEY OF MEDICINAL PLANTS USED BY THE TRADITIONAL HEALERS OF UGBINE FOR CANCER TREATMENT	34
	3.1	Introduction	34
	3.2	Materials and Methods	35
	3.2.1	Study Area	35
	3.2.2	Materials and Methods	36
	3.2.3	Sample Size and Sampling	37
	3.3	Results	38
	3.3.1	Socio-demographic Characteristics of Respondents	38
	3.3.2	Plant Species and Their Traditional Methods of Preparation	40
	3.3.3	Plant Identification and Authentication	40
	3.4	Discussion	41
	3.5	Conclusion	41
4		BIOASSAY- GUIDED ISOLATION AND CYTOTOXICITY EVALUATION OF EXTRACTS FROM <i>Synclisia scabrida</i> (Miers) Ex Oliv AND <i>Petiveria alliacea</i> Linnaeus	42
	4.1	Introduction	42
	4.2	Materials and Methods	43
	4.2.1	Chemicals and Reagents	43
	4.2.2	Preparation of Crude Extracts	43

4.2.3	Preliminary Phytochemical Studies of SS Root MeOH Extract, Fractions, and Sub-fractions	44
4.2.4	Chromatographic Studies	45
4.2.4.1	Column Chromatography	45
4.2.4.2	Thin Layer Chromatography (TLC)	45
4.2.4.3	Preparative Thin-Layer Chromatography (PTLC)	45
4.2.4.4	High Performance Liquid Chromatography	46
4.2.5	Bioassay-Guided Isolation of Active SS Root Fractions and Compounds	46
4.2.6	<i>In vitro</i> Test for Cytotoxicity Activity	47
4.2.6.1	Cell Culture	47
4.2.6.2	MTT Assay of SS Crude Root and Leaf Extracts	48
4.2.6.3	MTT Assay of SS Root MeOH Fractions and Sub-fractions	49
4.2.6.4	MTT Assay of PA Crude Leaf Extracts	50
4.2.7	Cell Cycle Analysis	50
4.2.8	Statistical analysis	50
4.3	Results	51
4.3.1	Physical Characteristics of SS Root Crude MeOH Extracts and Pure Compounds	51
4.3.2	Extracts Yields	52
4.3.3	Phytochemical Screening of the SS Root Crude MeOH Extract, Fractions, and Sub-fractions	52
4.3.4	Cytotoxic Activity of SS Root Crude Extracts Against Tumour Cells	58
4.3.5	Cytotoxic Activity of SS Leaf Crude Extracts Against Tumour Cells	62
4.3.6	The Effect of SS Root Fractions, and Sub-fractions Against Cancer Cells	62
4.3.7	Cytotoxic activity of PA leaf crude extracts against tumour cells	64
4.3.8	Cell cycle analysis of SS root MeOH extract on PANC-1 cells	65
4.4	Discussion	67
4.5	Conclusion	70
5	IN SILICO STUDY OF ANTICANCER AGENTS ISOLATED FROM <i>Synclisia scabrida</i> (Miers) Ex Oliv	71
5.1	Introduction	71
5.1.1	Molecular Docking	79
5.1.2	Docking Score	79
5.1.3	CHARMM-based DOCKER	80
5.2	Materials and Methods	80
5.2.1	Materials	80
5.2.2	Ligand and Protein Preparation	80

5.3	5.2.3 Molecular Docking	81
	5.2.4 Molecular Dynamics Simulations	81
	Results	82
	5.3.1 Molecular Docking of Cycleanine and its Analogues, SS_C2 and SS_C4, onto PARP1	84
	5.3.2 MD Simulation of Cycleanine/SS_C2/SS_C4-PARP1 Virtual Complex	86
	5.3.3 Cycleanine as a Caspase-3 Activator	90
	5.3.4 Molecular docking of cycleanine and Its analogues into c-Abl	94
	5.3.5 Molecular Docking of Cycleanine and Its Analogues onto CDK6	95
	5.3.6 Molecular Docking of Cycleanine and Its Analogues onto LIMK1 _{CAT} ^{D460N}	96
	5.3.7 Molecular Docking of Cycleanine and Its Analogues onto Akt	97
5.4	Discussion	98
5.5	Conclusion	102
6	STRUCTURAL ELUCIDATION AND CYTOTOXICITY EVALUATION OF COMPOUNDS ISOLATED FROM <i>synclisia scabrida</i> (Miers) Ex Oliv	
6.1	Introduction	103
6.2	Materials and methods	103
	6.2.1 NMR spectroscopy	104
	6.2.2 Fourier transform infrared (FTIR)	104
	6.2.3 Liquid chromatography-mass spectrometry quadrupole time of flight (LC/MS-QTOF)	105
	6.2.4 Cell culture	105
	6.2.5 MTT Assay of SS Root MeOH Pure Compounds	105
	6.2.6 Statistical analysis	106
6.3	Results	106
	6.3.1 Structural Identification of SS_C2	106
	6.3.2 Structural Identification of SS_C4	111
	6.3.3 Effect of SS Pure compounds Against Cancer Cells	116
6.4	Discussion	121
6.5	Conclusion	123
7	SUMMARY, GENERAL CONCLUSION, AND RECOMMENDATION FOR FUTURE RESEARCH	
7.1	Research Summary	124
7.2	General Conclusion	125
7.3	Recommendations for Future Research	126
7.4	Limitations of Current Study	127

REFERENCES	128
APPENDICES	171
BIODATA OF STUDENT	227
LIST OF PUBLICATIONS	228



LIST OF TABLES

Table	Page
2.1 Plant- isolated drugs used for research and clinical trials	16
3.1 Experience in cancer treatment	39
3.2 Recipes and traditional methods of preparing medicinal plants	40
4.1 Preliminary phytochemical analysis of <i>Synclisia scabrida</i> MeOH crude extract, fraction, and sub-fraction	44
4.2 Yield of crude extracts of <i>Synclisia scabrida</i> root and leaf and <i>Petiveria alliacea</i> leaf	52
4.3 Phytochemicals present in <i>Synclisia scabrida</i> root MeOH extract, fractions, and sub-fractions	57
4.4 Half maximal inhibitory concentration (IC_{50}) and selectivity index (SI) of <i>Synclisia scabrida</i> root crude MeOH extracts and gemcitabine on HCT-116, MCF-7, PANC-1 and PC-3 cells	59
4.5 Half maximal inhibitory concentration (IC_{50}) of <i>Synclisia scabrida</i> leaf extracts in cancer cells	62
4.6 Half maximal inhibitory concentration (IC_{50}) values of <i>Synclisia scabrida</i> root MeOH fractions against PANC-1 cells	63
4.7 Half maximal inhibitory concentration (IC_{50}) of <i>Synclisia scabrida</i> root MeOH sub-fractions	64
4.8 Half maximal inhibitory concentration (IC_{50}) values of <i>Petiveria alliacea</i> leaf extract against cancer cells	65
5.1 Cancer-related protein targets that interact with cycleanine and its analogues	74
5.2 Docking scores (CDOCKER energy in kcal/mol) of cycleanine and its analogues against the six selected target proteins	84
5.3 The docking scores (CDOCKER interaction energy in kcal/mol) of cycleanine and its analogues against the six selected apoptosis-related proteins	85
6.1 Properties of SS_C2 and cosculine	110

6.2	¹ H- and ¹³ C- NMR data of SS_C2 and cosculine (J values, in Hz, in parentheses)	110
6.3	Properties of SS_C4 and cycleanine	115
6.4	¹ H- and ¹³ C- NMR data of SS_C4 and cycleanine (J values, in Hz, in parentheses)	115
6.5	Half maximal inhibitory concentration (IC ₅₀) and selectivity indices (SI) of <i>Synclisia scabrida</i> root pure compounds and gemcitabine on HCT-116, MCF-7 and PANC-1	117

LIST OF FIGURES

Figure	Page
2.1 Chemical structures of liriodenine, cycleanine, clausenidin and isogravacridone chloride alkaloids	11
2.2 The structures of common flavonoids found in plants	13
2.3 Chemical structures of some of the promising anti-cancer steroid saponins/sapogenins	15
2.4 Extraction methods: percolation (a) and Soxhlet extraction (b).	20
2.5 Illustration of column chromatography	23
2.6 Illustration of HPLC	24
2.7 An illustration of bioassay-guided isolation of bioactive compounds from natural sources	25
2.8 Original photos of <i>Synclisia scabrida</i> (Miers) ex Oliv taken during the collection of the plant. The whole plant (a), aerial view (b), and root parts (c)	30
2.9 Bis-benzylisoquinoline alkaloids isolated from <i>S. scabrida</i> (Ohiri et al., 1983	30
2.10 Photos of <i>Petiveria alliacea</i> Linnaeus. Aerial view (a) and flowering parts and leaves (b)	32
2.11 Bioactive compounds isolated from <i>P. alliacea</i>	33
3.1 (a) Location of Edo State (study area); (b) location of the main studied area (in green)	36
3.2 Demographic characteristics of the respondents, in terms of gender (a), age (b), educational level (c), and religious beliefs (d)	39
4.1 Physical characteristics of <i>Synclisia scabrida</i> root HX (a), DCM (b), EA (c), and MeOH (d) crude extracts	51
4.2 Physical characteristics of <i>Synclisia scabrida</i> root pure compounds SS_C1 (a), SS_C2 (b), SS_C3 (c), and SS_C4 (d)	51
4.3 Flow chart for the bioassay-guided fractionation and isolation of cytotoxic compounds from <i>Synclisia scabrida</i> root (step 1)	53

4.4	Flow chart for the bioassay-guided fractionation and isolation of cytotoxic compounds from <i>Synclisia scabrida</i> root (step 2)	54
4.5	Flow chart for the bioassay-guided fractionation and isolation of cytotoxic compounds from <i>Synclisia scabrida</i> root (step 3)	55
4.6	Flow chart for the bioassay-guided fractionation and isolation of cytotoxic compounds from <i>Synclisia scabrida</i> root (step 4)	56
4.7	Detection of alkaloid compounds in the <i>Synclisia scabrida</i> root MeOH crude extract (c) and SSM_F4-8 (f) after spraying with Dragendorff's reagent, where red/orange spots are indicative of the presence of alkaloids	57
4.8	Representative dose-response curves showing the effect of crude MeOH extract of <i>Synclisia scabrida</i> root (in µg/mL) on % cell viability of tested cells after 96 h treatment	59
4.9	Representative dose-response curves showing the effect of gemcitabine on % cell viability of tested cells after 96 h treatment	60
4.10	Photomicrographs showing the effects of 0.1% DMSO (a) and 10 µg/mL <i>Synclisia scabrida</i> root MeOH extract (b) on HCT-116 cells after 96 h treatment (magnification = 400 x)	60
4.11	Photomicrographs showing the effects of 0.1% DMSO (a) and 10 µg/mL <i>Synclisia scabrida</i> root MeOH extract (b) on PC-3 cells after 96 h treatment (magnification = 400 x)	61
4.12	Photomicrographs showing the effects of 0.1% DMSO (a) and 10 µg/mL of <i>Synclisia scabrida</i> root MeOH extract (b) on MCF-7 cells after 96 h treatment (magnification = 400 x)	61
4.13	Photomicrographs showing the effects of 0.1% DMSO (a) and 10 µg/mL <i>Synclisia scabrida</i> root MeOH extract (b) on PANC-1 cells after 96 h treatment (magnification = 400 x)	62
4.14	Representative dose-response curves showing the effect of MeOH fractions of <i>Synclisia scabrida</i> root (in µg/mL) on % cell viability of PANC-1 cells after 96 h treatment	64
4.15	Representative DNA histogram of cell cycle analysis of PANC-1 cells at 96 h time point treated with 0.01% DMSO (a), 2.5 µg/mL (b), 5 µg/mL (c), 10 µg/mL (d) of <i>Synclisia scabrida</i> root MeOH extract and gemcitabine (in µM) (e) (n = 3; x-axis and y-axis represents DNA content and cell number, respectively)	66

4.16	Representative DNA histogram of cell cycle analysis of PANC-1 cells at 72 h time point treated with 0.01% DMSO (a), 2.5 µg/Ml (b), 5 µg/Ml (c), 10 µg/Ml (d) of <i>Synclisia scabrida</i> root MeOH extract or gemcitabine (in µM) €	67
5.1	Bis-benzylisoquinoline alkaloids isolated from <i>Synclisia scabrida</i> .	72
5.2	Comparison of the bound structures of crystal ligands (green stick) and the predicted docked conformations of the ligands (purple stick).	83
5.3	Probable binding interactions of cycleanine with the adjacent residues in the active sites of poly (ADP-ribose) polymerase (PARP) (a & b) as predicted from molecular docking	85
5.4	Intermolecular binding interactions of (a) SS_C2 and (b) SS_C4 with the poly (ADP-ribose) polymerase (PARP1) active site residues as predicted from molecular docking	86
5.5	Plots of the root mean square deviation (RMSD) and the root mean square fluctuation (RMSF) for the backbone of the simulated poly (ADP-ribose) polymerase (PARP1)–cycleanine complex	87
5.6	Snapshots of the simulated poly (ADP-ribose) polymerase (PARP1)–cycleanine virtual complex at 0, 25, and 50 ns	88
5.7	Plots of the root mean square deviation (RMSD) and the root mean square fluctuation (RMSF) for the backbone of the simulated apo (unliganded) form and poly (ADP-ribose) polymerase (PARP1)–ligand complexes	89
5.8	Two-dimensional interaction maps of snapshots of the simulated poly (ADP-ribose) polymerase (PARP1)–SS_C2 (a) and PARP1–SS_C4 (b) virtual complexes at 10, 30, and 50 ns	90
5.9	The three-dimensional structure of caspase-3 (PDB ID: 1NMS). (a) The dimer structure of mature caspase-3. It is composed of two small (blue and green) and two large (yellow and red) subunits	91
5.10	The allosteric site in procaspase-3. (a) Caspase-3 (PDB ID: 1NMS), with the orthosteric active site and the allosteric site at the central cavity (the dimer interface) shown using grey and green surface representations, respectively. (b) Procaspsase-3 (PDB ID: 4JQY), with the allosteric site at the dimer interface shown as a green surface	92
5.11	Cycleanine docked onto (a) procaspase-3 and (b) caspase-3	93
5.12	Probable binding interactions of (+)-coccoline-2'β-N-oxide with the adjacent residues in the active sites of the Ableson tyrosine kinase (c-Abl) (a & b) as predicted from molecular docking	94

5.13	Probable binding interactions of (+)-cocsoline-2'β-N-oxide with the adjacent residues in the active sites of cyclin-dependent kinase 6 (CDK6) (a & b) as predicted from molecular docking	95
5.14	Probable binding interactions of cocsuline with the adjacent residues in the active sites of the LIM kinase mutant (LIMK1 CATD460N)	97
5.15	Probable binding interactions of cocsuline with the adjacent residues in the active sites of Akt (a & b) as predicted from molecular docking	98
6.1	^1H -NMR (500 MHz, CD ₃ OD) spectrum of SS_C2	107
6.2	^{13}C -NMR (126 MHz, CD ₃ OD) spectrum of SS_C2	108
6.3	COSY spectrum of SS_C2.	108
6.4	HMBC spectrum of SS_C2	109
6.5	HSQC spectrum of SS_C2.	109
6.6	Proposed structure of SS_C2; chemical formula: C ₃₇ H ₃₈ N ₂ O ₄ , m/z: 574.28 (100.0%), 575.29 (40.0%), 576.29 (7.8%), amount: 18.7 mg	111
6.7	^1H -NMR (500 MHz, CD ₃ COCD ₃) spectrum of SS_C4	112
6.8	^{13}C -NMR (126 MHz, CD ₃ COCD ₃) spectrum of SS_C4	113
6.9	COSY spectrum of SS_C4	113
6.10	HMBC spectrum of SS_C4	114
6.11	HSQC spectrum of SS_C4	114
6.12	Proposed structure of SS_C4	115
6.13	Representative dose-response curves showing the effect of pure compounds (in $\mu\text{g/mL}$) isolated from <i>Synclisia scabrida</i> root on % cell viability of HCT-116 cells after 96 h treatment	117
6.14	Representative dose-response curves showing the effect of pure compounds (in $\mu\text{g/mL}$) isolated from <i>Synclisia scabrida</i> root on % cell viability of MCF-7 cells after 96 h treatment	118
6.15	Representative dose-response curves showing the effect of pure compounds (in $\mu\text{g/mL}$) isolated from <i>Synclisia scabrida</i> root on % cell viability of PANC-1 cells after 96 h treatment	118

6.16	Representative dose-response curves showing the effect of pure compounds (in $\mu\text{g/mL}$) isolated from <i>Synclisia scabrida</i> root and gemcitabine (in μM) on % cell viability of BEAS-2B cells after 96 h treatment	119
6.17	Representative dose-response curves showing the effect of pure compounds (in $\mu\text{g/mL}$) isolated from <i>Synclisia scabrida</i> root and gemcitabine (in μM) on % cell viability of BV-2 cells after 96 h treatment	119
6.18	Photomicrographs showing the effects of 0.1% DMSO (a) and 10 $\mu\text{g/mL}$ <i>Synclisia scabrida</i> root pure compound SS_C2 (b) on HCT-116 cells after 96 h treatment (magnification = 400 x)	120
6.19	Photomicrographs showing the effects of 0.1% DMSO (a) and 10 $\mu\text{g/mL}$ <i>Synclisia scabrida</i> root pure compound SS_C4 (b) on MCF-7 cells after 96 h treatment (magnification = 400 x)	120
6.20	Photomicrographs showing the effects of 0.1% DMSO (a) and 10 $\mu\text{g/mL}$ <i>Synclisia scabrida</i> root pure compound SS_C1 (b) on PANC-1 cells after 96 h treatment (magnification = 400 x)	121
7.1	Graphical abstract showing the isolation and characterisation of compounds (SS_C2 and SS_C4) isolated from <i>Synclisia scabrida</i> and their predicted mechanism of action as PARP1 inhibitors	126

LIST OF APPENDICES

Appendix		Page
3.1	University of Benin ethics approval	171
3.2	Questionnaire for assessment of the usage of herbs in treatment of cancer amongst rural community traditional healers in Akhuakhuaire and its environs, Benin city, Edo State, Nigeria	172
4.1	Second representative dose-response curve showing the effect of <i>Synclisia scabrida</i> root MeOH extract on % cell viability of HCT-116 cells after 96 h treatment	174
4.2	Third representative dose-response curve showing the effect of <i>Synclisia scabrida</i> root MeOH extract on % cell viability of HCT-116 cells after 96 h treatment	174
4.3	Second representative dose-response curve showing the effect of <i>Synclisia scabrida</i> root MeOH extract on % cell viability of PC-3 cells after 96 h treatment	175
4.4	Third representative dose-response curve showing the effect of <i>Synclisia scabrida</i> root MeOH extract on % cell viability of PC-3 cells after 96 h treatment	175
4.5	Second representative dose-response curve showing the effect of <i>Synclisia scabrida</i> root MeOH extract on % cell viability of MCF-7 cells after 96 h treatment	176
4.6	Third representative dose-response curve showing the effect of <i>Synclisia scabrida</i> root MeOH extract on % cell viability of MCF-7 cells after 96 h treatment	176
4.7	Second representative dose-response curve showing the effect of <i>Synclisia scabrida</i> root MeOH extract on % cell viability of PANC-1 cells after 96 h treatment	177
4.8	Third representative dose-response curve showing the effect of <i>Synclisia scabrida</i> root MeOH extract on % cell viability of PANC-1 cells after 96 h treatment	177
4.9	Second representative dose-response curve showing the effect of <i>Synclisia scabrida</i> leaf MeOH extract on % cell viability of HCT-116 cells after 96 h treatment	178

4.10	Third representative dose-response curve showing the effect of <i>Synclisia scabrida</i> leaf MeOH extract on % cell viability of HCT-116 cells after 96 h treatment	178
4.11	Second representative dose-response curve showing the effect of <i>Synclisia scabrida</i> leaf MeOH extract on % cell viability of MCF-7 cells after 96 h treatment	179
4.12	Third representative dose-response curve showing the effect of <i>Synclisia scabrida</i> leaf MeOH extract on % cell viability of MCF-7 cells after 96 h treatment	179
4.13	Second representative dose-response curve showing the effect of <i>Synclisia scabrida</i> leaf MeOH extract on % cell viability of PANC-1 cells after 96 h treatment	180
4.14	Third representative dose-response curve showing the effect of <i>Synclisia scabrida</i> leaf MeOH extract on % cell viability of PANC-1 cells after 96 h treatment	180
4.15	Second representative dose-response curve showing the effect of SSM_F1 on % cell viability of PANC-1 cells after 96 h treatment	181
4.16	Third representative dose-response curve showing the effect of SSM_F1 on % cell viability of PANC-1 cells after 96 h treatment	181
4.17	Second representative dose-response curve showing the effect of SSM_F2 on % cell viability of PANC-1 cells after 96 h treatment	182
4.18	Third representative dose-response curve showing the effect of SSM_F2 on % cell viability of PANC-1 cells after 96 h treatment	182
4.19	Second representative dose-response curve showing the effect of SSM_F3 on % cell viability of PANC-1 cells after 96 h treatment	183
4.20	Third representative dose-response curve showing the effect of SSM_F3 on % cell viability of PANC-1 cells after 96 h treatment	183
4.21	Second representative dose-response curve showing the effect of SSM_F4 on % cell viability of PANC-1 cells after 96 h treatment	184
4.22	Third representative dose-response curve showing the effect of SSM_F4 on % cell viability of PANC-1 cells after 96 h treatment	184
4.23	Second representative dose-response curve showing the effect of SSM_F5 on % cell viability of PANC-1 cells after 96 h treatment	185
4.24	Third representative dose-response curve showing the effect of SSM_F5 on % cell viability of PANC-1 cells after 96 h treatment	185

4.25	Second representative dose-response curve showing the effect of SSM_F6 on % cell viability of PANC-1 cells after 96 h treatment	186
4.26	Third representative dose-response curve showing the effect of SSM_F6 on % cell viability of PANC-1 cells after 96 h treatment	186
4.27	Second representative dose-response curve showing the effect of SSM_F7 on % cell viability of PANC-1 cells after 96 h treatment	187
4.28	Third representative dose-response curve showing the effect of SSM_F7 on % cell viability of PANC-1 cells after 96 h treatment	187
4.29	Second representative dose-response curve showing the effect of SSM_F8 on % cell viability of PANC-1 cells after 96 h treatment	188
4.30	Third representative dose-response curve showing the effect of SSM_F8 on % cell viability of PANC-1 cells after 96 h treatment	188
4.31	Second representative dose-response curve showing the effect of SSM_F9 on % cell viability of PANC-1 cells after 96 h treatment	189
4.32	Third representative dose-response curve showing the effect of SSM_F9 on % cell viability of PANC-1 cells after 96 h treatment	189
4.33	Second representative dose-response curve showing the effect of SSM_CF4-8 on % cell viability of PANC-1 cells after 96 h treatment	190
4.34	Third representative dose-response curve showing the effect of SSM_CF4-8 on % cell viability of PANC-1 cells after 96 h treatment	190
4.35	Second representative dose-response curve showing the effect of SSM_F4-8/CSF 8-21/3/S2 on % cell viability of PANC-1 cells after 96 h treatment	191
4.36	Third representative dose-response curve showing the effect of SSM_F4-8/CSF 8-21/3/S2 on % cell viability of PANC-1 cells after 96 h treatment	191
4.37	Second representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7 on % cell viability of HCT-116 cells after 96 h treatment	192
4.38	Third representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7 on % cell viability of HCT-116 cells after 96 h treatment	192
4.39	Second representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7/3+4 on % cell viability of HCT-116 cells after 96 h treatment	193

4.40	Third representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7/3+4 on % cell viability of HCT-116 cells after 96 h treatment	193
4.41	Second representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7 on % cell viability of MCF-7 cells after 96 h treatment	194
4.42	Third representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7 on % cell viability of MCF-7 cells after 96 h treatment	194
4.43	Second representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7/3+4 on % cell viability of MCF-7 cells after 96 h treatment	195
4.44	Third representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7/3+4 on % cell viability of MCF-7 cells after 96 h treatment	195
4.45	Second representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7 on % cell viability of PANC-1 cells after 96 h treatment	196
4.46	Third representative dose-response curve showing the effect of SSM_F 4-8/CSF 1-7 on % cell viability of PANC-1 cells after 96 h treatment	196
4.47	TLC plates showing the pure compounds isolated from <i>Synclisia scabrida</i> root methanol crude extract	197
4.48	HPLC spectrum of SS_C2	198
4.49	HPLC spectrum of SS_C4	198
4.50	Dose-response curves showing the effects of Petiveria alliacea DCM, DCM: MeOH and MeOH extracts on % cell viability on PC-3 cells after 96 h treatment	199
4.51	Dose-response curves showing the effects of Petiveria alliacea DCM, DCM: MeOH and MeOH extracts on % cell viability on MCF-7 cells after 96 h treatment	199
4.52	Dose-response curves showing the effect of Petiveria alliacea DCM DCM: MeOH and MeOH extracts on % cell viability of PANC-1 cells after 96 h treatment	200

4.53	Second (left) and third (right) representative DNA histogram profile of cell cycle analysis of PANC-1 cells at 96 h time point treated with 0.01% DMSO (a, b), 2.5 µg/mL (c, d), 5 µg/mL (e, f) of <i>Synclisia scabrida</i> root MeOH extract	201
4.54	Second and third representative DNA histogram profile of cell cycle analysis of PANC-1 cells at 96 h time point treated with 10 µg/mL (a and b) of <i>Synclisia scabrida</i> root MeOH extract or gemcitabine (in µM) (c)	202
4.55	Second representative DNA histogram profile of cell cycle analysis of PANC-1 cells at 72 h time point treated with 0.01% DMSO (a), 2.5 µg/mL (b), 5 µg/mL (c), 10 µg/mL (d) of <i>Synclisia scabrida</i> root MeOH extract or gemcitabine (in µM) (e)	203
4.56	Effect of SS Root crude MeOH extract on cell cycle distribution of PANC-1 Cells after 24, 48, 72 and 96 h treatment	204
5.1	The interaction energy analysis of compounds/ligands docked against PARP	205
5.2	The interaction energy analysis of compounds/ligands docked against c-Abl	206
5.3	The interaction energy analysis of compounds/ligands docked against CDK6	207
5.4	The interaction energy analysis of compounds/ligands docked LIMK1 _{CAT} ^{D460N}	208
5.5	The interaction energy analysis of compounds/ligands docked against Akt	209
6.1	¹ H-NMR spectrum of SS_C2	210
6.2	¹³ C-NMR spectrum of SS_C2.	210
6.3	COSY spectrum of SS_C2	211
6.4	FTIR spectrum of SS_C2	211
6.5	LC/MS Q-TOF analysis showing the mass spectrum of SS_C2 in the positive ESI mode	212
6.6	¹ H-NMR spectrum of SS_C4	212
6.7	¹³ C-NMR spectrum of SS_C4	213
6.8	COSY spectrum of SS_C4	213

6.9	FTIR spectrum of SS_C4	214
6.10	LC/MS Q-TOF analysis showing the mass spectrum of SS_C4 in the positive ESI mode	214
6.11	Second representative dose-response curve showing the effect of SS_C1 on % cell viability of HCT-116 cells after 96 h treatment	215
6.12	Third representative dose-response curve showing the effect of SS_C1 on % cell viability of HCT-116 cells after 96 h treatment	215
6.13	Second representative dose-response curve showing the effect of SS_C2 on % cell viability of HCT-116 cells after 96 h treatment	216
6.14	Third representative dose-response curve showing the effect of SS_C2 on % cell viability of HCT-116 cells after 96 h treatment	216
6.15	Second representative dose-response curve showing the effect of SS_C3 on % cell viability of HCT-116 cells after 96 h treatment	217
6.16	Third representative dose-response curve showing the effect of SS_C3 on % cell viability of HCT-116 cells after 96 h treatment	217
6.17	Second representative dose-response curve showing the effect of SS_C4 on % cell viability of HCT-116 cells after 96 h treatment	218
6.18	Third representative dose-response curve showing the effect of SS_C4 on % cell viability of HCT-116 cells after 96 h treatment	218
6.19	Second representative dose-response curve showing the effect of SS_C1 on % cell viability of MCF-7 cells after 96 h treatment	219
6.20	Third representative dose-response curve showing the effect of SS_C1 on % cell viability of MCF-7 cells after 96 h treatment	219
6.21	Second representative dose-response curve showing the effect of SS_C2 on % cell viability of MCF-7 cells after 96 h treatment	220
6.22	Third representative dose-response curve showing the effect of SS_C2 on % cell viability of MCF-7 cells after 96 h treatment	220
6.23	Second representative dose-response curve showing the effect of SS_C3 on % cell viability of MCF-7 cells after 96 h treatment	221
6.24	Third representative dose-response curve showing the effect of SS_C3 on % cell viability of MCF-7 cells after 96 h treatment	221
6.25	Second representative dose-response curve showing the effect of SS_C4 on % cell viability of MCF-7 cells after 96 h treatment	222

6.26	Third representative dose-response curve showing the effect of SS_C4 on % cell viability of MCF-7 cells after 96 h treatment	222
6.27	Second representative dose-response curve showing the effect of SS_C1 on % cell viability of PANC-1 cells after 96 h treatment	223
6.28	Third representative dose-response curve showing the effect of SS_C1 on % cell viability of PANC-1 cells after 96 h treatment	223
6.29	Second representative dose-response curve showing the effect of SS_C2 on % cell viability of PANC-1 cells after 96 h treatment	224
6.30	Third representative dose-response curve showing the effect of SS_C2 on % cell viability of PANC-1 cells after 96 h treatment	224
6.31	Second representative dose-response curve showing the effect of SS_C3 on % cell viability of PANC-1 cells after 96 h treatment	225
6.32	Third representative dose-response curve showing the effect of SS_C3 on % cell viability of PANC-1 cells after 96 h treatment	225
6.33	Second representative dose-response curve showing the effect of SS_C4 on % cell viability of PANC-1 cells after 96 h treatment	226
6.34	Third representative dose-response curve showing the effect of SS_C4 on % cell viability of PANC-1 cells after 96 h treatment	226

LIST OF ABBREVIATIONS

%	Percentage
°C	Degree Celsius
H	Hour
Nm	Nanometre
mg/kg	Milligram per kilogram
km ²	Square kilometre
G	Gram
w/w	Weight per weight
mL	Millilitre
mL/min	Millilitre per minute
U/mL	Unit per millilitre
µg/mL	Microgram per millilitre
v/v	Volume per volume
µL	Microlitre
µM	Micromolar
<	Less than
>	Greater than
Bar	Metric unit of pressure
Ns	Nanosecond
Å	Angstrom
kcal/mol	Kilocalorie per mole
K	Kelvin
m/z	Mass-to-charge ratio

g/mol	Gram per mol
δ_H	Chemical shift values of 1H -NMR
δ_C	Chemical shift values of ^{13}C -NMR
Ppm	Parts per million
S	Singlet
M	Multiplet
J	Coupling constants
Hz	Hertz
mg/ml	Milligram per millilitre
4T1	Colon cancer cells
1H -NMR	Proton NMR
2D NMR	Two-dimensional NMR
^{13}C -NMR	Carbon-13 NMR
ANOVA	One-way analysis of variance
AR	Androgen receptor
ACHN	Kidney cancer cell
ASTM	American Standard Test Sieve Series
ATP	Adenosine triphosphate
AMBER	Assisted Model Building with Energy Refinement
ATR	Ataxia telangiectasia and Rad3-related protein
AM1-BCC	semi-empirical (AM1) with bond charge correction (BCC)
A2780	Ovarian cancer cells
A549	Lung cancer cells
BEAS-2B	Human lung cells

BER	Base excision repair
BV-2	Murine cells
BBIQ	Bisbenzylisoquinoline
BETT	5-(2-benzofuryl)-4-phenyl-1,2,4-triazole-3-thiol
CFL1	Actin binding factor cofilin
c-Abl	Abelson tyrosine kinase
CDK	Cyclin dependent kinase
<i>COX-2</i>	Cyclooxygenase-2
CAM	Complementary and alternative medicine
CC	Column chromatography
COSY	Correlation spectroscopy
CH ₃	Methyl group
CH ₂	Methylene group
CH	Methine group
CHK1	Checkpoint kinase 1
CHARMM	Chemistry at Harvard Macromolecular Mechanics
CD ₃ OD	Deuterated methanol
CD ₃ COCD ₃	Deuterated acetone
DEPT	Distortionless enhancement by polarisation transfer
DNA	Deoxyribonucleic acid
DCM	Dichloromethane
DMEM	Dulbecco's Modified Eagle Medium
DMSO	Dimethyl sulfoxide
DS	Discovery Studio

DSB	Double-strand breaks
EDTA	Ethylenediaminetetraacetic acid
ER	Oestrogen receptor
ERK	Extracellular signal-regulated kinase
EA	Ethyl acetate
EGFR	Epidermal growth factor receptor
ESI	Electrospray ionization
FGFR	Fibroblast growth factor receptor
FRIN	Forestry Research Institute of Nigeria
FHI	Forest Herbarium Ibadan
FeCl ₃	Iron (III) chloride
GAFF	General AMBER Force Field
GLC	Gas-liquid chromatography
GSC	Gas-solid chromatography
GAE	Gallic acid equivalents
HDAC	Histone deacetylases
HCT-15	Colorectal cancer cell
HT-29	Colorectal cancer cell
HX	Hexane
HCT-116	Colorectal cancer cells
HPLC	High-performance liquid chromatography
HMBC	Heteronuclear multiple bond correlation
HSQC	Heteronuclear single quantum coherence
IL-6	Interleukin-6

<i>IL</i> -23	Interleukin-23
<i>IL</i> -1 β	Interleukin 1 beta
iNOS	Inducible nitric oxide synthase
IR	Infrared spectroscopy
IC ₅₀	Half maximal inhibitory concentration
IPA	Isopropanol
KRAS	Kirsten rat sarcoma viral oncogene
LOX-IMVI	Melanoma cell
LIMK1 _{CAT} ^{D460N}	LIM Domain Kinase 1 mutant
LC/MS-QTOF	Liquid chromatography-mass spectrometry quadrupole time of flight
miRNAs	MicroRNAs
MHz	Mega Hertz
MD	Molecular dynamics
MeOH	Methanol
MDA-MB-231	Breast cancer cell
MCF-7	Breast cancer cells
MS	Mass spectroscopy
MAPKs	Mitogen-activated protein kinases
MTT	Tetrazolium-based 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
MEK	Mitogen-activated protein kinase
mTOR	Mammalian target of rapamycin
nt	Not tested
na	Not available

nSH3	N-terminal SH3
NaCl	Sodium chloride
NVT	Amount of substance (N), volume (V) and temperature (T) ensemble
NPT	Constant-temperature, constant-pressure ensemble
NADPH	Reduced nicotinamide adenine dinucleotide phosphate
NMR	Nuclear magnetic resonance
NOESY	Nuclear Overhauser effect spectroscopy
NCI-H23	Non-Small Cell Lung Carcinoma
Ovcar-8	Ovarian cancer cells
PKB/Akt	Protein kinase B
PME	Particle Mesh Ewald
PBS	Phosphate buffer saline
PI	Propidium iodide
PA	<i>Petiveria alliacea</i> Linnaeus
PDB	Protein Data Bank
PAL	<i>Petiveria alliacea</i> leaf
PMF	Potential of mean force
PARG	PARP and poly (ADP-ribose) glycohydrolase
PC-3	Prostate cancer cell
PANC-1	Pancreatic cancer cells
PI3K	Phosphatidylinositol-3-kinase
PDK1	Pyruvate dehydrogenase kinase 1
PTLC	Preparative thin layer chromatography
RAF	Rapidly accelerated fibrosarcoma

Rt	Retention time
RNA	Ribonucleic acid
RPMI	Roswell Park Memorial Institute medium
RMSD	Root mean square deviations
RNase	Ribonuclease
RCSB	Research Collaboratory for Structural Bioinformatics
RMSF	Root mean square fluctuation
SS	<i>Synclisia scabrida</i> (Miers) ex Oliv
SSF	SS fraction
SSM_CF	SS methanol column fraction
SSM_F4–8/CSF/8–21	Column sub-fraction of SS methanol column fraction
SSM_F4–8/CSF/8–21/3/ S2	Column sub-fraction of SS methanol column fraction spot 2
SS_C1	SS compound 1
SS_C2	SS compound 2
SS_C3	SS compound 3
SS_C4	SS compound 4
SI	Selectivity index
SSB	Single-strand breaks
SPSS	Statistical Package for the Social Sciences
SSR	<i>Synclisia scabrida</i> root
SSL	<i>Synclisia scabrida</i> leaf
STAT3	Signal transducer and activator of transcription 3
SBDD	Structure-based drug design

TLC	Thin-layer chromatography
TPS	Total population sampling
TIC	Total ion chromatogram
UV	Ultraviolet
VMD	Visual molecular dynamics
VEGFR	Vascular endothelial growth factor receptor
WHO	World Health Organisation

Amino acids

Gly	Glycine
Arg	Arginine
Asp	Aspartic acid
His	Histidine
Tyr	Tyrosine
Met	Methionine
Ile	Isoleucine
Ser	Serine
Glu	Glutamic acid
Phe	Phenylalanine
Ala	Alanine
Asn	Asparagine
Lys	Lysine
Cys	Cysteine
Leu	Leucine

Val

Valine

Gln

Glutamine

CHAPTER 1

INTRODUCTION

1.1 Background of Study

Cancer poses a serious threat to global health, affecting both developed and developing countries. According to the World Health Organisation (WHO) 2020, non-communicable diseases are on the rise and caused 74% of all deaths in the world in 2019 (WHO, 2020). Cancer is a non-communicable disease; in 2020, new cases were estimated to have risen to 19.3 million and new deaths to 10 million globally (Sung et al., 2021). In 2020, cancer became the second leading cause of death in the United States (Siegel et al., 2020). Nevertheless, the cancer load is still alarming, with 1,898,160 new cancer cases and 608,570 cancer deaths estimated to happen in the United States in 2021 (Siegel et al., 2021). There are many types of cancer; globally, the most diagnosed is breast cancer with 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%) cancer (Sung et al., 2021). In 2020, lung cancer was the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancer (Sung et al., 2021).

Breast cancer is the most diagnosed cancer among American women. In 2021, it is estimated around 30% of newly diagnosed cancers in women will be breast cancers (American Cancer Society, 2021). In 2021, 281,550 new cases of invasive breast cancer are estimated in women in the U.S., together with 49,290 new cases of non-invasive (*in situ*) breast cancer, while around 43,600 women in the U.S. are expected to die in 2021 from breast cancer (American Cancer Society, 2021). Because the incidence increases annually by 0.4%, researchers have been challenged to identify new, more effective treatments (Jemal et al., 2017). If detected early, breast cancer patients can undertake breast-sparing surgery (lumpectomy) with radiotherapy or mastectomy to prevent spread (Moo et al., 2016). A common treatment regimen includes doxorubicin and cyclophosphamide for four cycles followed by paclitaxel for four cycles (AC-T). Current treatments include radiotherapy, surgery, and chemotherapeutic agents, which produce many adverse effects including nausea, fatigue, vomiting, weakened immunity, and hair loss (Costa et al., 2020).

Colorectal/colon cancer (CRC) is the second leading cause of death and the third most common malignant tumour globally. In 2018, 1.8 million new CRC cases were reported, out of which 881,000 deaths occurred; these figures accounted for about 10% of new cancer cases and deaths worldwide (Bray et al., 2018). In the early stages, CRC generally shows as an unusual growth on the inner walls of colon epithelial cells which could be removed by surgery when discovered early. Nevertheless, if not treated, the tumour cells spread to other organs, thereby becoming even insensitive to chemotherapy (Gothai et al., 2018).

Prostate cancer is the second most common tumour (following lung cancer) amongst males globally, with 1,276,106 new cases and 358,989 deaths (3.8% of all tumour deaths in men) in 2018 (Ferlay et al., 2019). Globally, as age increases, the incidence and mortality rate also increase, with 66 years taken as the average age at the time of diagnosis (Panigrahi et al., 2019). The early stage is without symptoms and needs little or no drug. However, the most common complaints are painful and recurrent urination, with nocturia. As the disease advances, urinary retention and back pain may occur.

Globally, pancreatic cancer (PaCa) is the seventh leading cause of cancer-related deaths (Rawla et al., 2019). In 2018, PaCa became the fourth leading cause of cancer-related death, in the United States (Soefje, 2019); that was 4.5% of all cancer deaths (Bray et al., 2018). The incidence and mortality rate of PaCa have been reportedly rising for decades, and PaCa is anticipated to be the second leading cause of cancer-related death in the United States in 2030 (Rahib et al., 2014). In the early stage, PaCa is symptomless (De et al., 2014). As it progresses, there is manifestation of nonspecific symptoms like jaundice, light-coloured stool, stomach pain, weight reduction, and weakness (Siegel, et al., 2018). The obtainable evaluation to diagnose PaCa can be nonspecific and may not identify patients at the early stage of the disease (De et al., 2014). Surgery, radiotherapy, and chemotherapy are conventional treatments that have been used to prolong patients' survival and alleviate symptoms.

Cancer treatment had been done with 'orthodox' chemotherapy drugs, for example, alkylating agents, intercalating drugs, topoisomerase inhibitors, antimetabolites, and antimitotic drugs (Meegan & O'Boyle, 2019). While targeted therapies like kinase inhibitors and monoclonal antibodies have also been used in specific types of cancer, not many can be completely cured with the available therapeutic options. Nevertheless, the success of therapy differs greatly depending on the cancer type and the stage of diagnosis (Meegan & O'Boyle, 2019). One of the major problems with anticancer therapy is the appearance of multidrug resistance – which reduces the efficacy - and relapse. Traditional chemotherapeutic agents directly target the DNA of the cell, but the cells counteract this through the development of resistance. Most of these agents are not selectively toxic to tumour cells; hence, manifestation of side effects in normal body tissues and cells is another limitation to their use. The side effects include peripheral neuropathy, bleeding, rash, allergic reaction, intense chills, shortness of breath, pain, prolonged diarrhoea or vomiting, and bloody stool or urine (Anderson & Matey, 2019; Olsen & Naseman, 2019). Furthermore, high costs limit the accessibility of traditional chemotherapeutic agents to the patients who need them, especially those in the rural communities (Meegan & O'Boyle, 2019). Cancer is now the second most costly disease in the United States, after heart disease: there was a cost increase from \$124 billion in 2010 to \$157 billion in 2020. The incidence of financial difficulty among cancer patients has been reported to be 49% from large meta-analyses (Gordon et al., 2017; Altice et al., 2016). This has become a major challenge in cancer patients and survivors. Therefore, there is an urgent need for a continuous search for new anticancer drugs that are more selective, efficacious, affordable, and safer.

Plant phytochemical constituents and their derivatives are promising alternatives to improve cancer treatment and, hence, patients' quality of life. Therefore, there has been a lot of research regarding traditional herbal medicines, which have a long history of use to treat various diseases. About 80% of the global population has used and continues to use traditional medicines for their primary health care needs (Illamola et al., 2019; Nagai & Kim, 2017). Furthermore, over 60% of drugs approved for cancer treatment have been derived from secondary metabolites of these medicinal plants. The secondary metabolites include alkaloids, glycosides, steroids, and flavonoids, among others (Newman & Cragg, 2020). These have been used greatly by pharmaceutical industries for drug synthesis (Cragg & Pezzuto, 2016; Sharanabasappa et al., 2007). Asian, African, and even developed nations have used medicinal plants in folk medicine.

Oteng et al. (2019) enumerated plants with proven efficacies for the treatment of various diseases. Many plant-derived chemotherapeutic agents have been used in the battle against cancer. They include vincristine (vinca alkaloid), paclitaxel (taxanes), etoposide (podophyllotoxin) (Li et al., 2017). Although the available synthetic drugs are being used, they are still limited due to the problem of resistance and toxicity to normal cells. Therefore, in a bid to discover alternative therapeutic agents for cancer treatment, traditional healers and herbal vendors have been involved to determine the herbs they have used for this purpose. This information may ultimately become a source of lead compounds and will promote the use of herbal medicine in cancer treatment.

The Ugbine community of Edo State, South South Nigeria, has been using herbs to treat cancer within their community without scientific validation. The cross-sectional survey which was conducted among the traditional healers and herbal vendors in the Ugbine community using a validated structured questionnaire, revealed the root of *Synclisia scabrida* (Miers) (local name: *omonuku*), belonging to the family Menispermaceae is the most effective and common herb used for treatment of cancer. *Petiveria alliacea* (PA) L. (family Phytolaccaceae) was also used in the community for cancer treatment. However, very few of the traditional healers had used herbs for cancer treatment; most of them had referred their cancer patients to hospitals.

S. scabrida is a familiar herb of tropical Africa present in South South Nigeria, Cameroon, Gabon, the Democratic Republic of the Congo and Angola (Hutchinson, 1954). In the agricultural sector of Nigeria, this shrub has been used as animal feed. The dried root of *S. scabrida* has been used traditionally to treat lower abdominal pains, listlessness, psychosis (Sokomba et., 1986.), sexually transmitted diseases, and bacterial infections (Sokomba et., 1986). Despite the promising use of this plant, there has been no known scientific study conducted to validate its use for the treatment of cancer. Because it grows commonly in the farmlands in the said community and is consumed by the indigenous population for treatment of cancer without any obvious toxicity, it was selected for this study in search of a cancer therapeutic agent that is less expensive and safer.

1.2 Statement of Research Problem

Although many breakthroughs have been made in cancer treatment, it remains a great challenge to both patients and physicians given the failure to achieve a total cure with the current drugs due to the development of resistance, adverse effect, and the imposed significant financial toxicity on the patients (Soefje, 2019). Furthermore, the use of the herb *S. scabrida* and *P. alliacea* in cancer treatment was verbally reported by herbal practitioners in Ugbine community. However, there is no scientific validation and report on the treatment of cancer with SS and the use of PA in prostate and pancreatic cancers.

1.3 Hypotheses of Study

1. Root extracts and isolates of *P. alliacea* and *S. scabrida* exert anticancer activities against cancer cells.
2. Methanol (MeOH) extract is the most active towards PANC-1 cell.
3. SS MeOH extract arrest PANC-1 cell cycle progression.
4. Isolated compounds from SS inhibit PARP1.

1.4 General Objective

To assess the anticancer activity of crude leaf extract of *P. alliacea* and whole root extract of *S. scabrida* together with its major isolated bioactive constituents against colon, prostate, breast, and pancreatic cancer cells *in vitro*.

1.5 Specific Objectives

1. To identify the plants used by Ugbine traditional healers for cancer treatment, through an ethnobotanical study.
2. To evaluate crude extracts of *P. alliacea* and *S. scabrida* for anticancer activity.
3. To identify the most potent extract of *S. scabrida* and the most sensitive cells for further studies.
4. To assess the effect of *S. scabrida* most abundant and potent extract on cell cycle progression.
5. To perform bioactivity-guided isolation of cytotoxic compounds from the roots of *S. scabrida*.
6. To determine the mechanism of actions of the active compounds from *S. scabrida*. using *in silico* molecular docking and molecular dynamics simulation studies.

REFERENCES

- Abubakar, A. R., & Haque, M. (2020). Preparation of medicinal plants: Basic extraction and fractionation procedures for experimental purposes. *Journal of Pharmacy and Bioallied Sciences*, 12, 1-10. https://doi.org/10.4103/jpbs.JPBS_175_19.
- Acevedo-Rodríguez, P., Strong, M. T. (2013). Catalogue of Seed Plants of the West Indies . Smithsonian Contributions to Botany, Number 98. By Pedro Acevedo-Rodríguez and Mark T. Strong. Washington (DC): Smithsonian Institution Scholarly Press. xxv + 1192 p.; no index. ISSN: 0081-024X (print); 1938-2. *The Quarterly Review of Biology*, 88(1), 54. <https://doi.org/10.1086/669312>.
- Adams, L. S., Phung, S., Yee, N., Seeram, N. P., Li, L., & Chen, S. (2010). Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. *Cancer Research*, 70(9), 3594–3605. <https://doi.org/10.1158/0008-5472.CAN-09-3565>.
- Adamska, A., Domenichini, A., & Falasca, M. (2017). Pancreatic ductal adenocarcinoma: Current and evolving therapies. *International Journal of Molecular Sciences*, 18(7), 1338. <https://doi.org/10.3390/ijms18071338>.
- Adetutu, A., Morgan, W. A., & Corcoran, O. (2011). Ethnopharmacological survey and in vitro evaluation of wound-healing plants used in South-western Nigeria. *Journal of Ethnopharmacology*, 137(1), 50–56. <https://doi.org/10.1016/j.jep.2011.03.073>.
- Adlard, E. R. (2011). High Performance Liquid Chromatography in Phytochemical Analysis. In Monika Waksmundzka-Hajnos & Joseph Sherma (Eds.), *Chromatographia*. (74, 749). CRC Press, Taylor and Francis Group, LLC Boca Raton London. <https://doi.org/10.1007/s10337-011-2106-3>.
- Afonne, O.J., Orisakwe, O.E., Obi, E., Orish, C., Akumka, D.D. (2000). Some pharmacological properties of *Synclisia scabrida* III. *Indian Journal of Pharmacology*, 32(3), 231–241.
- Afsar, T., Razak, S., Khan, M. R., Mawash, S., Almajwal, A., Shabir, M., & Haq, I. U. (2016). Evaluation of antioxidant, anti-hemolytic and anticancer activity of various solvent extracts of Acacia hydaspica R. Parker aerial parts. *BMC Complementary and Alternative Medicine*, 16, 258. <https://doi.org/10.1186/s12906-016-1240-8>
- Agarwal, S., Jangir, D. K., Mehrotra, R., Lohani, N., & Rajeswari, M. R. (2014). A structural insight into major groove directed binding of nitrosourea derivative nimustine with DNA: A spectroscopic study. *PLoS ONE*, 9, 104–115. <https://doi.org/10.1371/journal.pone.0104115>.
- Ahmed, D., Eide, P., Eilertsen, I., Danielsen, S. A., Eknæs, M., Hektoen, M., Lind, G. E., & Lothe R. A. (2013). Epigenetic and genetic features of 24 colon cancer cell lines. *Oncogenesis*, 2, e71. <https://doi.org/10.1038/oncsis.2013.35>.

- Aiyelaagbe, O. O., Hamid, A. A., Fattorusso, E., Taglialatela-Scafati, O., Schröder, H. C., & Müller, W. E. G. (2011). Cytotoxic activity of crude extracts as well as of pure components from jatropha species, plants used extensively in african traditional medicine. *Evidence-Based Complementary and Alternative Medicine*, 2011, 134954. <https://doi.org/10.1155/2011/134954>.
- Aiyeloja, A. A., & Bello, O. A. (2006). Ethnobotanical potentials of common herbs in Nigeria: a case study of Enugu state. *Educational Research and Review*, 1(1), 16–22.
- Ajibesin, K. K., Ekpo, B. A., Bala, D. N., Essien, E. E., & Adesanya, S. A. (2008). Ethnobotanical survey of Akwa Ibom State of Nigeria. *Journal of Ethnopharmacology*, 115(3), 38. <https://doi.org/10.1016/j.jep.2007.10.021>.
- Akdogan, E. D., Erman, B., Yelekc, K. (2011). In silico design of novel and highly selective lysine-specific histone demethylase inhibitors. *Turkish Journal Chemistry*, 35(2011), 523–542. <https://doi.org/https://doi.org/10.3906/kim-1102-985>.
- Akintan, M. O., Akinneye, J. O., & Ilelakinwa, O. B. (2021). Efficacy of Petiveria Alliacea (Linneaus) leaf and root bark powder in the control of filariasis vector Culex Quinquefasciatus. *The Journal of Basic and Applied Zoology*, 82: 5. <https://doi.org/10.1186/s41936-020-00199-3>.
- Alao, J. P. (2007). The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. In *Molecular Cancer* (p. 6:24). <https://doi.org/10.1186/1476-4598-6-24>.
- Al-Bukhaiti, W. Q., Noman, A., Qasim, A. S., & Al-Farga, A. (2017). Gas Chromatography: Principles, Advantages and Applications in Food Analysis. *International Journal of Agriculture Innovations and Research*, 6(1), 123–128.
- Al-Shar'i, N. A. (2021). Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations. *Journal of Biomolecular Structure and Dynamics*, 39(17), 6689–6704. <https://doi.org/10.1080/07391102.2020.1800514>.
- Al-Shar'i, N. A., & Al-Balas, Q. A. (2019). Molecular Dynamics Simulations of Adenosine Receptors: Advances, Applications and Trends. *Current Pharmaceutical Design*, 25(7), 783–816. <https://doi.org/10.2174/1381612825666190304123414>.
- Al-Shar'i, N. A., & Alnabulsi, S. M. (2016). Explaining the autoinhibition of the SMYD enzyme family: A theoretical study. *Journal of Molecular Graphics and Modelling*, 68, 147–157. <https://doi.org/10.1016/j.jmgm.2016.07.001>.
- Al-Shar'i, N. A. & Musleh, S. (2020). Identification of CHK1 Kinase Inhibitors Using Structure Based Pharmacophore Modelling and Molecular Docking. *Indian Journal of Pharmaceutical Sciences*, 82(3), 472–482. <http://doi.org/10.36468/pharmaceutical-sciences.670>.

- Al-Shar'i, N., & Musleh, S. S. (2021). CHK1 kinase inhibition: identification of allosteric hits using MD simulations, pharmacophore modeling, docking and MM-PBSA calculations. *Molecular Diversity*, 82(3), 472–482. <https://doi.org/10.1007/s11030-021-10202-w>.
- Altice, C. K., Banegas, M. P., Tucker-Seeley, R. D., & Yabroff, K. R. (2016). Financial Hardships Experienced by Cancer Survivors: A Systematic Review. *Journal of the National Cancer Institute*, 109(2), djw205. <https://doi.org/10.1093/jnci/djw205>.
- Alvarez-Sala, A., Attanzio, A., Tesoriere, L., Garcia-Llatas, G., Barberá, R., & Cilla, A. Apoptotic effect of a phytosterol-ingredient and its main phytosterol (β -sitosterol) in human cancer cell lines. *International Journal of Food Sciences and Nutrition*, 70(3), 323-334. <https://doi.org/10.1080/09637486.2018.1511689>.
- Alegre, J. C., & Clavo, M. (2007). Petiveria alliacea L. In G. H. Schmelzer & Gurib- A. Fakim (Eds.), *Plant Resources of Tropical Africa*. Wageningen, Netherlands: PROTA. <http://www.prota4u.org/search.asp>.
- Allnér, O., Nilsson, L., & Villa, A. (2012). Magnesium ion-water coordination and exchange in biomolecular simulations. *Journal of Chemical Theory and Computation*, 8(4), 1493–1502. <https://doi.org/10.1021/ct3000734>.
- Altemimi, A., Lakhssassi, N., Baharlouei, A., Watson, D., & Lightfoot, D. (2017). Phytochemicals: Extraction, Isolation, and Identification of Bioactive Compounds from Plant Extracts. *Plants*, 6(4), 42. <https://doi.org/10.3390/plants6040042>.
- Altice, C. K., Banegas, M. P., Tucker-Seeley, R. D., & Yabroff, K. R. (2017). Financial hardships experienced by cancer survivors: A systematic review. In *Journal of the National Cancer Institute*, 109(2), djw205. <https://doi.org/10.1093/jnci/djw205>.
- Amanam, I., & Chung, V. (2018). Targeted therapies for pancreatic cancer. *Cancers* 10,(2), 1–14. <https://doi.org/10.3390/cancers10020036>.
- Amaro, R. E., Baudry, J., Chodera, J., Demir, Ö., McCammon, J. A., Miao, Y., & Smith, J. C. (2018). Ensemble Docking in Drug Discovery. *Biophysical Journal*, 114, 2271–2278). <https://doi.org/10.1016/j.bpj.2018.02.038>.
- Amin, A., Gali-Muhtasib, H., Ocker, M., & Schneider-Stock, R. (2009). Overview of major classes of plant-derived anticancer drugs. *International Journal of Biomedical Science*, 5(1), 1–11.
- Anderson, M. K., Matey, L. (2019). Overview of cancer and cancer treatment. In (Olsen, M. M., LeFebvre, K. B., Brassil, K. J., eds.). *Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice*. Pittsburgh, PA: Oncology Nursing Society, 2019, 25-50.

- Angerhofer, C. K., Guinaudeau, H., Wongpanich, V., Pezzuto, J. M., & Cordell, G. A. (1999). Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids. *Journal of Natural Products*, 62(1), 59–66. <https://doi.org/10.1021/np980144f>.
- Anowi, F. C., Onyekaba, T.U., Eze, C. C., Ike, C. & Ezenachi, V. C. (2013). Preliminary Phytochemical investigations and evaluation of Antimicrobial activity of n-hexane extract of the leaves of *Synclisia scabrida* family menispermaceae. *Research Journal of Pharmaceutical Sciences*, 2(3), 1–5.
- Arcaro, A., & Guerreiro, A. (2007). The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications. *Current Genomics*, 8(5), 271–306. <https://doi.org/10.2174/138920207782446160>.
- Arslan, C., & Yalcin, S. (2014). Current and future systemic treatment options in metastatic pancreatic cancer. *Journal of Gastrointestinal Oncology*, 5(4), 280–295. <https://doi.org/10.3978/j.issn.2078-6891.2014.030>.
- Ashraf, M. A. (2020). Phytochemicals as Potential Anticancer Drugs: Time to Ponder Nature's Bounty. *BioMed Research International*, 2020, 8602879. <https://doi.org/10.1155/2020/8602879>.
- Aung, T. N., Qu, Z., Kortschak, R. D., & Adelson, D. L. (2017). Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. *International Journal of Molecular Science,s* 18(3), 656. <https://doi.org/10.3390/ijms18030656>.
- Ayele, T. T. (2018). A Review on Traditionally Used Medicinal Plants/Herbs for Cancer Therapy in Ethiopia: Current Status, Challenge and Future Perspectives. *Organic Chemistry: Current Research*, 7(2), 8. <https://doi.org/10.4172/2161-0401.1000192>.
- Ayodele, O. D., Oyegbade, O., & Oseni, S. R. (2015). Phytochemical Analysis and Antioxidant Activities of Dry and Fresh Leaves of Petivera alliacea and Ocimum gratissimum. *International Journal of Sciences: Basic and Applied Research (IJSBAR)*, 24(3), 1-13. Retrieved from <https://gssrr.org/index.php/JournalOfBasicAndApplied/article/view/4596>.
- Azwanida, N. N. (2015). A review on the extraction methods use in medicinal plants, principle, strength, and limitation. *Medicinal & Aromatic Plants*, 4(3), 196. <https://doi.org/DOI: 10.4172/2167-0412.1000196>.
- Badisa, R. B., Ayuk-Takem, L. T., Ikediobi, C. O., & Walker, E. H. (2006). Selective anticancer activity of pure licamichauxiioic-B acid in cultured cell lines. *Pharmaceutical Biology*, 44(2), 141–145. <https://doi.org/10.1080/13880200600592301>.
- Bagheri-Yarmand, R., Mazumdar, A., Sahin, A. A., & Kumar, R. (2006). LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. *International Journal of Cancer*, 118(11), 2703–2710. <https://doi.org/10.1002/ijc.21650>.

- Banu, K. S., & Cathrine, L. (2015). General Techniques Involved in Phytochemical Analysis. *International Journal of Advanced Research in Chemical Science*, 2(4), 25–32.
- Barlesi, F., Villani, P., Doddoli, C., Gimenez, C., Kleisbauer, J. P. (2004). Gemcitabine-induced severe pulmonary toxicity. *Fundamental and Clinical Pharmacology*, 18(1): 85–91.
- Basati, G., Saffari-Chaleshtori, J., Abbaszadeh, S., Asadi-Samani, M., & Ashrafi-Dehkordi, K. (2019). Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6. *Current Drug Research Reviews*, 11(2), 135–141. <https://doi.org/10.2174/2589977511666191018180001>.
- Behbahani, T. E., Thierse, C., Baumann, C., Holl, D., Bastian, P. J., von Ruecker, A., Müller, S. C., Ellinger, J., & Hauser, S. (2012). Tyrosine kinase expression profile in clear cell renal cell carcinoma. *World Journal of Urology*, 30(4), 559–565. <https://doi.org/10.1007/s00345-011-0767-z>.
- Behzad, S., Ebrahim, K., Mosaddegh, M., & Haeri, A. (2016). Primula auriculata extracts exert cytotoxic and apoptotic effects against HT-29 human colon Adenocarcinoma cells. *Iranian Journal of Pharmaceutical Research*, 15, 311–322. <https://doi.org/10.22037/ijpr.2016.1779>.
- Bellacosa, A., Chan, T. O., Ahmed, N. N., Datta, K., Malstrom, S., Stokoe, D., McCormick, F., Feng, J., & Tsichlis, P. (1998). Akt activation by growth factors is a multiple-step process: The role of the PH domain. *Oncogene*, 17, 313–325. <https://doi.org/10.1038/sj.onc.1201947>.
- Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P. (2000). The Protein Data Bank. *Nucleic Acids Research*, 28(1), 235–242. <https://doi.org/10.1093/nar/28.1.235>.
- Bezerra, J. N. S. (2006). Composição fitoquímica, atividade fitonematicida e inseticida de tipi (*Petiveria alliacea*), Master's Dissertation. Universidade Federal do Ceará, Departamento de Química Orgânica e Inorgânica. Fortaleza-CE.
- Bhakuni, D. S., & Joshi, P. P. (1975). Alkaloids of *Coccus pendulus* (forsk) diels. *Tetrahedron*, 31(20), 2575–2579. [https://doi.org/10.1016/0040-4020\(75\)80272-9](https://doi.org/10.1016/0040-4020(75)80272-9).
- BIOVIA, D. S. (2016). *Discovery Studio 2016*, San Diego: Dassault Systèmes.
- BIOVIA, D. S. (2020). *Discovery Studio*, San Diego: Dassault Systèmes.
- Biswas, K. K., Tancharon, S., Sarker, K. P., Kawahara, K. I., Hashiguchi, T., & Maruyama, I. (2006). Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (HuH-7) through the activation of JNK1/2 and the downregulation of Akt. *FEBS Letters*, 580, 703–710. <https://doi.org/10.1016/j.febslet.2005.12.048>.

- Blandino, G., & Di Agostino, S. (2018). New therapeutic strategies to treat human cancers expressing mutant p53 proteins. *Journal of Experimental and Clinical Cancer Research*, 37(1): 30. <https://doi.org/10.1186/s13046-018-0705-7>.
- Body, M. R., & Paull, K. D. (1995). Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. *Drug Development Research*, 34(2), 91–109. <https://doi.org/10.1002/ddr.430340203>.
- Bohio, A. A., Wang, R., Zeng, X., & Ba, X. (2020). c-Abl-mediated tyrosine phosphorylation of DNA damage response proteins and implications in important cellular functions (Review). *Molecular Medicine Reports*, 22: 612-619. <https://doi.org/10.3892/mmr.2020.11156>.
- Böhm, H. J. (1992). The computer program LUDI: A new method for the de novo design of enzyme inhibitors. *Journal of Computer-Aided Molecular Design*, 6(1), 61–78. <https://doi.org/10.1007/BF00124387>.
- Bona, K., Dussel, V., Orellana, L., Kang, T., Geyer, R., Feudtner, C., Wolfe, J. (2014). Economic impact of advanced pediatric cancer on families. *Journal of Pain and Symptom Management*, 47(3), 594–603. <https://doi.org/10.1016/j.jpainsymman.2013.04.003>
- Bourhia, M., Abdelaziz Shahat, A., Mohammed Almarfadi, O., Ali Naser, F., Mostafa Abdelmageed, W., Ait Haj Said, A., El Gueddari, F., Naamane, A., Benbacer, L., & Khilil, N. (2019). Ethnopharmacological Survey of Herbal Remedies Used for the Treatment of Cancer in the Greater Casablanca-Morocco. *Evidence-Based Complementary and Alternative Medicine*, 2019, 1613457. <https://doi.org/10.1155/2019/1613457>.
- Boyington, J. C., Gaffney, B. J., & Amzel, L. M. (1993). The three-dimensional structure of an arachidonic acid 15-lipoxygenase. *Science*, 260(5113), 1482–1486. <https://doi.org/10.1126/science.8502991>.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394-424. <https://doi.org/10.3322/caac.21492>.
- Brown, D. (1995). Encyclopaedia of herbs and their uses. *Dorling Kindersley*, pp: 424.
- Bryant, H. E., Petermann, E., Schultz, N., Jemth, A. S., Loseva, O., Issaeva, N., Johansson, F., Fernandez, S., McGlynn, P., & Helleday, T. (2009). PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. *EMBO Journal*, 28, 2601-2615. <https://doi.org/10.1038/emboj.2009.206>.
- Buckner, C. A., Lafrenie, R. M., Dénommée, J. A., Caswell, J. M., & Want, D. A. (2018). Complementary and alternative medicine use in patients before and after a cancer diagnosis. *Current Oncology*, 25(4), e275-e281. <https://doi.org/10.3747/co.25.3884>.

- Bukowski, K., Kciuk, M., & Kontek, R. (2020). Mechanisms of multidrug resistance in cancer chemotherapy. *International Journal of Molecular Sciences*, 21, 3233. <https://doi.org/10.3390/ijms21093233>.
- Butler, M. S. (2004). The role of natural product chemistry in drug discovery. *Journal of Natural Products*, 67, 2141-2153. <https://doi.org/10.1021/np040106y>.
- Camacho, M.d.R., Phillipson, J.D., Croft, S.L., Rock, P., Marshal, S.J., Schiff Jr., P. L. (2002). In vitro activity of Triclisia patents and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei brucei. *Phytotherapy Research*, 16, 432–436.
- Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018). The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. *CA: A Cancer Journal for Clinicians*, 68(2), 153–165. <https://doi.org/10.3322/caac.21443>.
- Carter, S. J. (2008). *Cooper and Gunn's Tutorial pharmacy* (12th editi). CBS Publishers and Distributors PVT LTD. <https://doi.org/10.1093/clinchem/30.9.1594>.
- Case, D.A., Darden, T.A., Cheatham III, T.E., Simmerling, C.L., Wang, J., Duke, R.E., Luo, R., Walker, R.C., Zhang, W., Merz, K.M., Roberts, B., Hayik, S., Roitberg, A., Seabra, G., Swails, J., Götz, A.W., Kolossváry, I., Wong, K.F., Paesani, F., ... Kollman, P.A. (2012). AMBER 12. University of California, San Francisco.
- Castro, J. S., Trzaskowski, B., Deymier, P. A., Bucay, J., Adamowicz, L., & Hoying, J. B. (2009). Binding affinity of fluorochromes and fluorescent proteins to Taxol™ crystals. *Materials Science and Engineering C*, 29, 1609–1615. <https://doi.org/10.1016/j.msec.2008.12.026>.
- Chabner, B. A., & Roberts, T. G. (2005). Review: Timeline: Chemotherapy and the war on cancer. *Nature Reviews. Cancer*, 5, 65–72.
- Chalhoub, N., & Baker, S. J. (2009). PTEN and the PI3-kinase pathway in cancer. *Annual Review of Pathology: Mechanisms of Disease*, 4:127–150. <https://doi.org/10.1146/annurev.pathol.4.110807.092311>.
- Che, E., Gao, Y., Wan, L., Zhang, Y., Han, N., Bai, J., Li, J., Sha, Z., & Wang, S. (2015). Paclitaxel/gelatin coated magnetic mesoporous silica nanoparticles: Preparation and antitumor efficacy in vivo. *Microporous and Mesoporous Materials*, 204, 226–234. <https://doi.org/10.1016/j.micromeso.2014.11.013>.
- Chekole, G., Asfaw, Z., & Kelbessa, E. (2015). Ethnobotanical study of medicinal plants in the environs of Tara-gedam and Amba remnant forests of Libo Kemkem District, northwest Ethiopia. *Journal of Ethnobiology and Ethnomedicine*, 11, 4. <https://doi.org/10.1186/1746-4269-11-4>.

- Chen, S-H., & Cheung C. H. A. (2018). Challenges in Treating Estrogen Receptor-Positive Breast Cancer. *Estrogen*. Wahid Ali Khan, IntechOpen. <https://doi.org/10.5772/intechopen.79263>.
- Chen, X., Dang, T-T. T., & Facchini, P. J. (2015). Noscapine comes of age. In *Phytochemistry*, 111:7–13. <https://doi.org/10.1016/j.phytochem.2014.09.008>.
- Cheng, Y., He, W., & He, Y. (2018). Gleditsia Saponin C Induces A549 Cell Apoptosis via Caspase-Dependent Cascade and Suppresses Tumor Growth on Xenografts Tumor Animal Model. *Frontiers in Pharmacology*, 8, 988. <https://doi.org/10.3389/fphar.2017.00988>.
- Choi, S. U., Park, S. H., Kim, K. H., Choi, E. J., Kim, S., Park, W. K., Zhang, Y. H., Kim, H. S., Jung, N. P., & Lee, C. O. (1998). The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. *Anti-Cancer Drugs*, 9(3), 255–261. <https://doi.org/10.1097/00001813-199803000-00008>.
- Chota, A., George, B. P., & Abrahamse, H. (2020). Potential treatment of breast and lung cancer using dicoma anomala, an african medicinal plant. *Molecules*, 25(19), 4435. <https://doi.org/10.3390/molecules25194435>.
- Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P., & Prakash, O. (2020). Phytochemicals in cancer treatment: From preclinical studies to clinical practice. *Frontiers in Pharmacology*, 10:1614. <https://doi.org/10.3389/fphar.2019.01614>.
- Christian Reinhardt, H., & Yaffe, M. B. (2013). Phospho-Ser/Thr-binding domains: Navigating the cell cycle and DNA damage response. *Nature Reviews Molecular Cell Biology*, 14(9), 563–580. <https://doi.org/10.1038/nrm3640>.
- Chu, E., & DeVita Jr., V. T. (2019). Physician's Cancer Chemotherapy Drug Manual. In *Cancer research*. Jones & Bartlett Learning publisher.
- Collins, M. A., & di Maglino, M. P. (2014). Kras as a key oncogene and therapeutic target in pancreatic cancer. In *Frontiers in Physiology*, 4, 407. <https://doi.org/10.3389/fphys.2013.00407>.
- Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R. P., Rabinovich, B. A., Hann, B., Dankort, D., Spellman, P. T., Phillips, W. A., Gray, J. W., & McMahon, M. (2012). A Central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. *Cancer Discovery*, 2, 685–693. <https://doi.org/10.1158/2159-8290.CD-11-0347>.
- Cornblatt, B. S., Ye, L., Dinkova-Kostova, A. T., Erb, M., Fahey, J. W., Singh, N. K., Chen, M. S. A., Stierer, T., Garrett-Mayer, E., Argani, P., Davidson, N. E., Talalay, P., Kensler, T. W., & Visvanathan, K. (2007). Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. *Carcinogenesis*, 28(7), 1485–1490. <https://doi.org/10.1093/carcin/bgm049>.

- Costa, B., Amorim, I., Gärtner, F., & Vale, N. Understanding Breast cancer: from conventional therapies to repurposed drugs. *European Journal of Pharmaceutical Science*, 151, 105401. <https://doi.org/10.1016/j.ejps.2020.105401>
- Cragg, G. M., Newman, D. J., & Yang, S. S. (2016). Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. *Journal of Natural Products* 69(3), 488–498. <https://doi.org/10.1021/np0581216>.
- Cragg, G. M., & Pezzuto, J. M. (2016). Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents. *Medical Principles and Practice*, 25(2), 41–59. <https://doi.org/10.1159/000443404>.
- Cragg, G. M., & Newman, D. J. (2005). Plants as source of anticancer agents. *Journal of Ethnopharmacology*, 100(1–2), 72–79. <https://doi.org/DOI:10.1016/j.jep.2005.05.011>.
- Ćujić, N., Šavikin, K., Janković, T., Pljevljakušić, D., Zdunić, G., & Ibrić, S. (2016). Optimization of polyphenols extraction from dried chokeberry using maceration as traditional technique. *Food Chemistry*, 194, 135–142. <https://doi.org/10.1016/j.foodchem.2015.08.008>.
- Cui, Y., Liu, B., Sun, X., Li, Z., Chen, Y., Guo, Z., Liu, H., Li, D., Wang, C., Zhu, X., & Shi, Y. (2020). Protective effects of alfalfa saponins on oxidative stress-induced apoptotic cells. *Food and Function*, 11, 8133–8140. DOI: 10.1039/DFOO1797C.
- Dabbs, D. M., Mulders, N., & Aksay, I. A. (2006). Solvothermal removal of the organic template from L 3 (“sponge”) templated silica monoliths. *Journal of Nanoparticle Research*, 8, 603–614. <https://doi.org/10.1007/s11051-005-9063-4>.
- Dall'Acqua, S. (2014). Natural Products As Antimitotic Agents. *Current Topics in Medicinal Chemistry*, 14, 2272–2285. <https://doi.org/10.2174/1568026614666141130095311>.
- D'Amours, D., Germain, M., Orth, K., Dixit V. M. & Guy G. Poirier (1998). Proteolysis of Poly (ADP-Ribose) Polymerase by Caspase 3: Kinetics of Cleavage of Mono (ADP-Ribosylated and DNA-Bound Substrates. *Radiation Research*, 150, (1), 3–10.
- D'Amours, D., Desnoyers, S., D'Silva, I., Poirier, G. G. (1999). Poly (ADP-ribosyl)ation reactions in the regulation of nuclear functions. *Biochemical Journal*, 342, 249–268.
- Davila, M. (2003). LIM Kinase 1 Is Essential for the Invasive Growth of Prostate Epithelial Cells: IMPLICATIONS IN PROSTATE CANCER. *Journal of Biological Chemistry*, 278, (38), 36868–36875.

- De Andrade, T. M., De Melo, A. S., Dias, R. G. C., Varela, E. L. P., De Oliveira, F. R., Vieira, J. L. F., De Andrade, M. A., Baetas, A. C., Monteiro, M. C., & Maia, C. D. S. F. (2012). Potential behavioral and pro-oxidant effects of Petiveria alliacea L. extract in adult rats. *Journal of Ethnopharmacology*, 143, 604–610. <https://doi.org/10.1016/j.jep.2012.07.020>.
- De La Cruz M. S., Young, A. P., Ruffin, M. T. (2014). Diagnosis and management of pancreatic cancer. *BMC Cancer*, 89(8), 626–632.
- de Lima, T. C. M., Morato, G. S., & Takahashi, R. N. (1991). Evaluation of antinociceptive effect of Petiveria alliacea (Guiné) in animals. *Memórias Do Instituto Oswaldo Cruz*, 86(2), 153-158. <https://doi.org/10.1590/s0074-02761991000600035>.
- De Wet, H., Fouche, G., & Van Heerden, F. R. (2009). In vitro cytotoxicity of crude alkaloidal extracts of South African Menispermaceae against three cancer cell lines. *African Journal of Biotechnology*, 8(14), 3332–3335. <https://doi.org/10.4314/ajb.v8i14.61091>.
- Deb, P. K., Al-Shar'i, N. A., Venugopala, K. N., Pillay, M., & Borah, P. (2021). In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 36(1), 869–884. <https://doi.org/10.1080/14756366.2021.1900162>.
- Debray, M., Plat, M., & Le Men, J. (1966). Alcaloïdes des Ménispermacées africaines Epinetrum cordifolium et Epinetrum magenotii: isolement de la cycleanine, de la nor-cycléanine et de l'isochondrodendrine. *Annales Pharmaceutiques Francaises*, 24(7), 551–558.
- Deer, E. L., Jessica, G. H., Coursen, J. D., Shea, J. E., Josephat, N., Scaife, C. L., Firpo, M. A., Mulvihill, S. J. (2010). Phenotype and genotype of pancreatic cancer cell lines. *Pancreas*, 39: 425–435. doi: 10.1097/MPA.0b013e3181c15963.
- Deepa, B., Babaji, H. V., Hosmani, J. V., Alamir, A. W. H., Mushtaq, S., Raj, A. T., & Patil, S. (2019). Effect of Tinospora cordifolia-derived phytocomponents on cancer: A systematic review. *Applied Sciences (Switzerland)* 9, 5147. <https://doi.org/10.3390/app9235147>.
- Deepak, R. N. V. K., Abdullah, A., Talwar, P., Fan, H., & Ravanan, P. (2018). Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases. *Proteins: Structure, Function and Bioinformatics*, 86(11), 1202–1210. <https://doi.org/10.1002/prot.25601>.
- DeLano, W. L. (2020). The PyMOL Molecular Graphics System, Version 2.3. In *Schrödinger LLC*.
- Dembitsky, V. M., Gloriozova, T. A., & Poroikov, V. V. (2015). Naturally occurring plant isoquinoline N-oxide alkaloids: Their pharmacological and SAR activities. *Phytomedicine*, 22(1), 183–202. <https://doi.org/10.1016/j.phymed.2014.11.002>.

- Denais, C., & Lammerding, J. (2014). Nuclear mechanics in cancer. *Advances in Experimental Medicine and Biology*, 773, 435–470. https://doi.org/10.1007/978-1-4899-8032-8_20.
- Deng, Q. P., Wang, M. J., Zeng, X., Chen, G. G., & Huang, R. Y. (2017). Effects of glycyrrhizin in a mouse model of lung adenocarcinoma. *Cellular Physiology and Biochemistry*, 41(4), 1383 – 1392. <https://doi.org/10.1159/000467897>.
- Dewick, P. M. (2002). Medicinal Natural Products: A Biosynthetic Approach, Second Edition - Dewick - Wiley Online Library. *Medicinal Natural Products* (2nd ed.). John Wiley & Sons, New York.
- Dey, P., Kundu, A., Kumar, A., Gupta, M., Lee, B. M., Bhakta, T., Dash, S., & Kim, H. S. (2020). Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids). *Recent Advances in Natural Products Analysis* 2020, 505–567. <https://doi.org/10.1016/b978-0-12-816455-6.00015-9>.
- Di, B., Pan, B., Ge, L., Ma, J., Wu, Y., & Guo, T. (2018). Targeted agents for patients with advanced/metastatic pancreatic cancer: A protocol for systematic review and network meta-analysis. *Medicine (Baltimore)*, 97(13), e0115. <https://doi.org/10.1097/MD.00000000000010115>.
- Di Stasi, L. C., Costa, M., Mendaçolli, S. L. J., Kirizawa, M., Gomes, C., & Trolin, G. (1988). Screening in mice of some medicinal plants used for analgesic purposes in the state of São Paulo. *Journal of Ethnopharmacology*, 24(2–3), 205–211. [https://doi.org/10.1016/0378-8741\(88\)90153-5](https://doi.org/10.1016/0378-8741(88)90153-5).
- Di Stasi, L. C., Feitosa, S. B., & Hiruma-Lima, C. A. (2002). Caryophyllales medicinais. In: Di Stasi L. C., Hiruma-Lima, C. A., (eds.). *Medicinal Plants in the Amazonian region and Atlantic Forest*. 2nd ed. São Paulo: Editora Unesp. 149-173.
- Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortes, J., Dieras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., Yardley, D. A., Frenzel, M., Koustenis, A., & Baselga, J. (2017). MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, n patients with refractory HR+/HER2- metastatic breast cancer. *Clinical Cancer Research*, 23(17), 5218–5224. <https://doi.org/10.1158/1078-0432.CCR-17-0754>.
- Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020). The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. *International Journal of Molecular Sciences* 21(6), 1960. <https://doi.org/10.3390/ijms21061960>.
- Dizdar, O., Bilgin, E., Akin, S., Kilickap, S., & Hayran, M. (2017). Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database. *Journal of the Balkan Union of Oncology*, 22(2), 530–534.

- Dou, J., Wang, Z., Ma, L., Peng, B., Mao, K., Li, C., Su, M., Zhou, C., & Peng, G. (2018). Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence. *Oncotarget*, 9(28), 20089–20102. <https://doi.org/10.18632/oncotarget.24015>.
- Doughari, J. H.. (2012). Phytochemicals: extraction methods, basic structures and mode of action as potential chemotherapeutic agents. In V. R (Ed.), *Phytochemicals - A Global Perspective of Their Role in Nutrition and Health*. IntechOpen. <https://doi.org/doi: 10.5772/26052>.
- Drew, Y. (2015). The development of PARP inhibitors in ovarian cancer: From bench to bedside. *British Journal of Cancer*, 113(S1), S3-S9. <https://doi.org/10.1038/bjc.2015.394>
- Du, G., Zhao, H., Song, Y., Zhang, Q., & Wang, Y. (2011). Rapid simultaneous determination of isoflavones in Radix puerariae using high-performance liquid chromatography-triple quadrupole mass spectrometry with novel shell-type column. *Journal of Separation Science*, 34(19), 2576–2585. <https://doi.org/10.1002/jssc.201100295>.
- Du, Q., Guo, X., Wang, M., Li, Y., Sun, X., & Li, Q. (2020). The application and prospect of CDK4/6 inhibitors in malignant solid tumors. *Journal of Hematology and Oncology* 13, 41. <https://doi.org/10.1186/s13045-020-00880-8>.
- Efferth, T. (2005). Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. *Drug Resistance Updates*, 8(1–2), 85–97. <https://doi.org/10.1016/j.drup.2005.04.003>.
- Ehnblom, A., Hall, M. B., & Gladysz, J. A. (2019). Origin of Shielding and Deshielding Effects in NMR Spectra of Organic Conjugated Polyynes. *Organic Letters*, 21(2019), 753–757. <https://doi.org/10.1021/acs.orglett.8b03990>.
- El-Feky, A. M., & Aboulthana, W. M. (2016). Phytochemical and Biochemical Studies of Sage (*Salvia officinalis* L.). *UK Journal of Pharmaceutical Biosciences*, 4(5), 56–62. <https://doi.org/10.20510/ukjpb/4/i5/118037>.
- Eldridge, M. D., Murray, C. W., Auton, T. R., Paolini, G. V., & Mee, R. P. (1997). Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. *Journal of Computer-Aided Molecular Design*, 11(5), 425–445. <https://doi.org/10.1023/A:1007996124545>.
- Esubalew, S. T., Belete, A., Lulekal, E., Gabriel, T., Engidawork, E., & Asres, K. (2017). Review of Ethnobotanical and Ethnopharmacological Evidences of some Ethiopian Medicinal Plants traditionally used for the Treatment of Cancer. *Ethiopian Journal of Health Development*, 31(3), 161-187. <https://doi.org/10.4314/ejhd.v3i13>.
- Etikan, I., Musa, S. A., & Alkassim, R. S. (2016). Comparison of Convenience Sampling and Purposive Sampling. *American Journal of Theoretical and Applied Statistics*, 5(1), 1–4. <https://doi.org/10.11648/j.ajtas.20160501.11>.

- Eustermann, S., Videler, H., Yang, J. C., Cole, P. T., Gruszka, D., Veprintsev, D., & Neuhaus, D. (2011). The DNA-binding domain of human PARP-1 interacts with DNA single-strand breaks as a monomer through its second zinc finger. *Journal of Molecular Biology*, 407(1), 149–170. <https://doi.org/10.1016/j.jmb.2011.01.034>.
- Evans WC. (1989). *Trease and Evans' Pharmacognosy* (13th ed.). Cambridge University Press.
- Fadrná, E., Hladečková, K., & Koča, J. (2005). Long-range electrostatic interactions in molecular dynamics: An endothelin-1 case study. *Journal of Biomolecular Structure and Dynamics*, 23(2), 151–162. <https://doi.org/10.1080/07391102.2005.10531229>.
- Feldman, T., Kabaleeswaran, V., Jang, S. B., Antczak, C., Djaballah, H., Wu, H., & Jiang, X. (2012). A Class of Allosteric Caspase Inhibitors Identified by High-Throughput Screening. *Molecular Cell*, 47(4), 585–595. <https://doi.org/10.1016/j.molcel.2012.06.007>.
- Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2014). GLOBOCAN 2012 v10, *Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11*. Lyon, France: International Agency for Research on Cancer.
- Ferlay, J., Ervik, M., & Lam, F. (2019). Global Cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer 2018. *International Agency for Research on Cancer*.
- Ferreira, L. G., dos Santos, R. N., Oliva, G., & Andricopulo, A. D. (2015). Molecular docking and structure-based drug design strategies. *Molecules*, 20, 13384–13421. <https://doi.org/doi: 10.3390/molecules200713384>.
- Fletcher, R. & Reeves, C. M. (1964). Function minimization by conjugate gradients. *The Computer Journal*, 7(2), 149–154. <https://doi.org/10.1093/comjnl/7.2.149>.
- Floyd, A. C., Oikpor, R. & Ekene, B. (2016). An Assessment of Climate Change in Benin City, Edo State, Nigeria. *FUTY Journal of the Environment*, 10(1), 87–94.
- Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring 1. Method and assessment of docking accuracy. *Journal of Medicinal Chemistry*, 47(7), 1739–1749. <https://doi.org/10.1021/jm0306430>.
- Fox, M. A. & Whitesell, J. K. (1997). *Organic Chemistry*, 2nd edition, 1997. Jones & Bartlett Learning, LLC publisher, United States.

- Fujiwara, H., Hosokawa, M., Zhou, X., Fujimoto, S., Fukuda, K., Toyoda, K., Nishi, Y., Fujita, Y., Yamada, K., Yamada, Y., Seino, Y., & Inagaki, N. (2008). Curcumin inhibits glucose production in isolated mice hepatocytes. *Diabetes Research and Clinical Practice*, 80(2), 185–191. <https://doi.org/10.1016/j.diabres.2007.12.004>.
- Fürst, R., & Zündorf, I. (2015). Evidence-Based Phytotherapy in Europe: Where Do We Stand? *Planta Medica* 81, 962–967. <https://doi.org/10.1055/s-0035-1545948>.
- Gali-Muhtasib, H., Hmadi, R., Kareh, M., Tohme, R., & Darwiche, N. (2015). Cell death mechanisms of plant-derived anticancer drugs: Beyond apoptosis. *Apoptosis* 20(12), 1531–1562. <https://doi.org/10.1007/s10495-015-1169-2>.
- Gao, S., Li, X., Ding, X., Qi, W., & Yang, Q. (2017). Cepharanthine induces autophagy, apoptosis and cell cycle arrest in breast cancer cells. *Cellular Physiology and Biochemistry*, 41(4), 1633–1648. <https://doi.org/10.1159/000471234>.
- Gbolade, A. (2012). Ethnobotanical study of plants used in treating hypertension in Edo State of Nigeria. *Journal of Ethnopharmacology*, 144(1), 1–10. <https://doi.org/10.1016/j.jep.2012.07.018>.
- Gehringer, M., & Laufer, S. A. (2019). Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. *Journal of Medicinal Chemistry*, 62(12), 5673–5724. <https://doi.org/10.1021/acs.jmedchem.8b01153>.
- Gérard, C., & Goldbeter, A. (2009). Temporal self-organization of the cyclin/Cdk network driving the mammalian cell cycle. *Ecological Engineering*, 106(51), 21643–21648. <https://doi.org/10.1016/j.ecoleng.2008.12.036>.
- Gérard, C., & Goldbeter, A. (2012). From quiescence to proliferation: Cdk oscillations drive the mammalian cell cycle. *Frontiers in Physiology*, 3, 413. <https://doi.org/10.3389/fphys.2012.00413>.
- Goel, A., Boland, C. R., & Chauhan, D. P. (2001). Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. *Cancer Letters*, 172(2), 111–118. [https://doi.org/10.1016/S0304-3835\(01\)00655-3](https://doi.org/10.1016/S0304-3835(01)00655-3).
- Goncalves, M. D., Hopkins, B. D., & Cantley, L. C. (2018). Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. *New England Journal of Medicine*, 379(21), 2052–2062. <https://doi.org/10.1056/nejmra1704560>.
- Gordon, L. G., Merollini, K. M. D., Lowe, A., & Chan, R. J. (2017). A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can't Pay the Co-Pay. *Patient*, 10(3), 295–309. <https://doi.org/10.1007/s40271-016-0204-x>.
- Gothai, S., Muniandy, K., Esa, N. M., Subbiah, S. K., & Arulselvan, P. (2018). Anticancer potential of Alternanthera sessilis extract on HT-29 human colon cancer cells. *Asian Pacific Journal of Tropical Biomedicine*, 8, 394–402. <https://doi.org/10.4103/2221-1691.239427>.

- Greenwell, M., & Rahman, P. K. S. M. (2015). Medicinal Plants: Their Use in Anticancer Treatment. *International Journal of Pharmaceutical Sciences and Research*, 6(10), 4103–4112. [https://doi.org/10.13040/IJPSR.0975-8232.6\(10\).4103-12](https://doi.org/10.13040/IJPSR.0975-8232.6(10).4103-12).
- Greuber, E. K., Smith-Pearson, P., Wang, J., & Pendergast, A. M. (2013). Role of ABL family kinases in cancer: From leukaemia to solid tumours. *Nature Reviews Cancer*, 13(8), 559–571. <https://doi.org/10.1038/nrc3563>.
- Griffin, A. M., Butow, P. N., Coates, A. S., Childs, A. M., Ellis, P. M., Dunn, S. M., & Tattersall, M. H. N. (1996). On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993. *Annals of Oncology*, 7(2), 189–195. <https://doi.org/10.1093/oxfordjournals.annonc.a010548>.
- Guthrie, N., Gapor, A., Chambers, A. F., & Carroll, K. K. (1997). Palm oil tocotrienols and plant flavonoids act synergistically to inhibit proliferation of estrogen receptor-negative MDA-MB-231 and -positive MCF-7 human breast cancer cells in culture. *Asia Pacific J Clin Nutr*, 6, 41–45.
- Habli, Z., Toumeh, G., Fatfat, M., Rahal, O. N., & Gali-Muhtasib, H. (2017). Emerging cytotoxic alkaloids in the battle against cancer: Overview of molecular mechanisms. *Molecules* 22: 250. <https://doi.org/10.3390/molecules22020250>.
- Hammonds, K. D., & Ryckaert, J. P. (1991). On the convergence of the SHAKE algorithm. *Computer Physics Communications*, 62(2), 336–351. [https://doi.org/10.1016/0010-4655\(91\)90105-T](https://doi.org/10.1016/0010-4655(91)90105-T).
- Hao, J., Yang, X., Ding, X. L., Guo, L. M., Zhu, C. H., Ji, W., Zhou, T., & Wu, X. Z. (2016). Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErBB3 Phosphorylation. *Scientific Reports*, 6, 32809. <https://doi.org/10.1038/srep32809>.
- Harborne, A. J. (1998). *Phytochemical Methods A Guide to Modern Techniques of Plant Analysis* (3rd ed.). Springer Netherlands. <https://doi.org/10.1046/j.1365-3059.1999.00318.x>
- Hardy, J. A., Lam, J., Nguyen, J. T., O'Brien, T., & Wells, J. A. (2004). Discovery of an allosteric site in the caspases. *Proceedings of the National Academy of Sciences of the United States of America*, 101(34), 12461–12466. <https://doi.org/10.1073/pnas.0404781101>.
- Hariono, M., Abdullah, N., Damodaran, K. V., Kamarulzaman, E. E., Mohamed, N., Hassan, S. S., Shamsuddin, S., & Wahab, H. A. (2016). Potential New H1N1 Neuraminidase Inhibitors from Ferulic Acid and Vanillin: Molecular Modelling, Synthesis and in Vitro Assay. *Scientific Reports*, 6, 38692. <https://doi.org/10.1038/srep38692>.
- Harvey, D. (2020). Classifying Separation Techniques. In *Chemistry LibreTexts*. <https://chem.libretexts.org/@go/page/162885>.

- Hashemi, G. N., Najafi, M., Salehi, E., Farhood, B., & Mortezaee, K. (2019). Cyclooxygenase-2 in cancer: A review. *Journal of Cellular Physiology*, 234(5), 5683-5699. <https://doi.org/10.1002/jcp.27411>.
- He, B.-C., Gao, J. L., Luo, X., Luo, J., Shen, J., Wang, L., Zhou, Q., Wang, Y. I. T., Luu, H. H., Haydon, R. C., Wang, C. Z., Du, W., Yuan, C. S., He, T. C., & Zhang, B. Q. (2011). Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/β-catenin signaling. *International Journal of Oncology*, 38(2), 437–445. <https://doi.org/10.3892/ijo.2010.858>.
- He, B.-C., Gao, J. L., Zhang, B. Q., Luo, Q., Shi, Q., Kim, S. H., Huang, E., Gao, Y., Yang, K., Wagner, E.R., Wang, L., Tang, N., Luo, J., Liu, X., Li, M., Bi, Y., Shen, J., Luther, G., Hu, N., ... He, T. C. (2011). Tetrandrine inhibits Wnt/beta-catenin signaling and suppresses tumor growth of human colorectal cancer. *Molecular Pharmacology*, 79(2), 211-219. <https://doi.org/10.1124/mol.110.068668>.
- Heftmann, E. (1992). Chromatography fundamentals and applications of chromatographic and electrophoretic methods - Part A: fundamentals and techniques. *Journal of Chromatography Library* (5th ed.). Elsevier B.V.
- Helleday, T. (2017). Chemotherapy-induced toxicity-A secondary effect caused by released DNA? *Annals of Oncology*, 28(9): 2054-2055. <https://doi.org/10.1093/annonc/mdx349>.
- Henary, M., Narayana, L., Ahad, S., Gundala, S. R., Mukkavilli, R., Sharma, V., Owens, E. A., Yadav, Y., Nagaraju, M., Hamelberg, D., Tandon, V., Panda, D., & Aneja, R. (2014). Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity. *Biochemical Pharmacology*, 92, 192–205. <https://doi.org/10.1016/j.bcp.2014.07.020>
- Hernández, J. F., Urueña, C. P., Sandoval, T. A., Cifuentes, M. C., Formentini, L., Cuezva, J. M., & Fiorentino, S. (2017). A cytotoxic Petiveria alliacea dry extract induces ATP depletion and decreases β-F1-ATPase expression in breast cancer cells and promotes survival in tumor-bearing mice. *Revista Brasileira de Farmacognosia*, 27(3), 306–314. <https://doi.org/10.1016/j.bjp.2016.09.008>.
- Hernández, J. F., Urueña, C. P., Cifuentes, M. C., Sandoval, T. A., Pombo, L. M., Castañeda, D., Asea, A., & Fiorentino, S. (2014). A Petiveria alliacea standardized fraction induces breast adenocarcinoma cell death by modulating glycolytic metabolism. *Journal of Ethnopharmacology*, 153(3), 641–649. <https://doi.org/10.1016/j.jep.2014.03.013>.
- Hiben, M. G., Kamelia, L., de Haan, L., Spenkinkel, B., Wesseling, S., Vervoort, J., & Rietjens, I. M. C. M. (2019). Hazard assessment of Maerua subcordata (Gilg) DeWolf. for selected endpoints using a battery of in vitro tests. *Journal of Ethnopharmacology*, 241, 111978. <https://doi.org/10.1016/j.jep.2019.111978>.

- Hidalgo, M., Cascinu, S., Kleeff, J., Labianca, R., Löhr, J. M., Neoptolemos, J., Real, F. X., Van Laethem, J. L., Heinemann, V. (2015). Addressing the challenges of pancreatic cancer: future directions for improving outcomes. *Pancreatology*, 15(1), 8-18. doi: 10.1016/j.pan.2014.10.001.
- Higuchi, O., Baeg, G. H., Akiyama, T., & Mizuno, K. (1996). Suppression of fibroblast cell growth by overexpression of LIM-kinase 1. *FEBS Letters*, 396, (1), 81–86.
- Holt, P. A., Chaires, J. B., & Trent, J. O. (2008). Molecular docking of intercalators and groove-binders to nucleic acids using autodock and surflex. *Journal of Chemical Information and Modeling*, 48, 1602–1615. <https://doi.org/10.1021/ci800063v>.
- Homeyer, N., Horn, A. H. C., Lanig, H., & Sticht, H. (2006). AMBER force-field parameters for phosphorylated amino acids in different protonation states: Phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine. *Journal of Molecular Modeling*, 12(3), 281–289. <https://doi.org/10.1007/s00894-005-0028-4>.
- Hong, C. Y., Wang, C. P., Huang, S. S., & Hsu, F. L. (1995). The inhibitory effect of tannins on lipid peroxidation of rat heart mitochondria. *The Journal of Pharmacy and Pharmacology*, 47(2), 138–142. <http://www.ncbi.nlm.nih.gov/pubmed/7602469>.
- Horwitz, K. B., Costlow, M. E., & McGuire, W. L. (1975). MCF-7: a human breast cancer cell line with estrogen, progesterone, and glucocorticoid receptors. *Steroids*, 26(6), 785–795.
- Hoshyar, R., Mohaghegh, Z., Torabi, N., & Abolghasemi, A. (2015). Antitumor activity of aqueous extract of *Ziziphus jujube* fruit in breast cancer: An in vitro and in vivo study. *Asian Pacific Journal of Reproduction*, 4(2), 116–122. [https://doi.org/10.1016/S2305-0500\(15\)30007-5](https://doi.org/10.1016/S2305-0500(15)30007-5).
- Hossain, M. A., Al-Hdhrami, S. S., Weli, A. M., Al-Riyami, Q., & Al-Sabahi, J. N. (2014). Isolation, fractionation and identification of chemical constituents from the leaves crude extracts of *Mentha piperita* L grown in Sultanate of Oman. *Asian Pacific Journal of Tropical Biomedicine*, 4, S368–S372. <https://doi.org/10.12980/APJTB.4.2014C1051>.
- Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985). Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. *Journal of Biological Chemistry*, 260(27), 14873–14878. [https://doi.org/10.1016/s0021-9258\(17\)38654-4](https://doi.org/10.1016/s0021-9258(17)38654-4).
- Hua, P., Sun, M., Zhang, G., Zhang, Y., Tian, X., Li, X., Cui, R., & Zhang, X. (2015). Cepharanthe induces apoptosis through reactive oxygen species and mitochondrial dysfunction in human non-small-cell lung cancer cells. *Biochemical and Biophysical Research Communications*, 460, 136–142. <https://doi.org/10.1016/j.bbrc.2015.02.131>.

- Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. *Journal of Molecular Graphics*, 14(1), 33-38. [https://doi.org/DOI: http://doi.org/10.1016/0263-7855\(96\)00018-5](https://doi.org/DOI: http://doi.org/10.1016/0263-7855(96)00018-5).
- Hutchinson, J. & Dalziel, J. M. (1954). *Flora of West Tropical Africa (Vol. 1). Part 1.* 2nd Edition. Crown Agents for Overseas Governments Administrations, London.
- Idowu, O. A., Soniran, O. T., Ajana, O., & Aworinde, D. O. (2010). Ethnobotanical survey of antimalarial plants used in Ogun State, Southwest Nigeria. *African Journal of Pharmacy and Pharmacology*, 4(2), 55–60.
- Idu, M., Erhabor, J. O., & Odia, E. A. (2009). Morphological and Anatomical Studies of the Leaf and Stem of Some Medicinal Plants: *Stachytarpheta jamaicensis*. *Ethnobotanical Leaflets*, 13, 548–563.
- Illamola, S. M., Amaeze, O. U., Krepkova, L. V., Birnbaum, A. K., Karanam, A., Job, K. M., Bortnikova, V. V., Sherwin, C. M. T., & Enioutina, E. Y. (2019). Use of herbal medicine by pregnant women: What physicians need to know. *Frontiers in Pharmacology*, 10, 1483. <https://doi.org/10.3389/fphar.2019.01483>.
- Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., Parasuraman, S., & Shapiro, G. I. (2016). A phase i study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. *Clinical Cancer Research*, 22(23), 1–35. <https://doi.org/10.1158/1078-0432.CCR-16-1248>.
- Ingle, K. P., Deshmukh, A. G., Padole, D. A., Dudhare, M. S., Moharil, M. P., & Khelurkar, V. C. (2017). Phytochemicals: Extraction methods, identification and detection of bioactive compounds from plant extracts. *Journal of Pharmacognosy and Phytochemistry*, 6, 32–36.
- Institute, N. C. (2013). SEER cancer statistics review, 1. *National Cancer Institute*. (. <http://www.seer.cancer.gov>.
- Iqbal, J., Abbasi, B. A., Mahmood, T., Kanwal, S., Ali, B., Shah, S. A., & Khalil, A. T. (2017). Plant-derived anticancer agents: A green anticancer approach. *Asian Pacific Journal of Tropical Biomedicine*, 7(12): 1129-1150. <https://doi.org/10.1016/j.apjtb.2017.10.016>.
- Isah, T. (2016). Anticancer alkaloids from trees: Development into drugs. In *Pharmacognosy Reviews*, 10(20), 90–99. <https://doi.org/10.4103/0973-7847.194047>.
- Izaguirre, J.A., Daniel P. C., Wozniak, J. M., & Skeel R. D. (2001). Langevin stabilization of molecular dynamics. *The Journal of Chemical Physics*, 114(5), 2090–2098. <https://doi.org/DOI: http://doi.org/10.1063/1.1332996>.

- Jada, S. R., Hamzah, A. S., Lajis, N. H., Saad, M. S., Stevens, M. F. G., & Stanslas, J. (2006). Semisynthesis and cytotoxic activities of andrographolide analogues. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 21(2), 145–155. <https://doi.org/10.1080/14756360500499988>.
- Jain, A., Tripathi, R., Turpin, C. P., Wang, C., & Plattner, R. (2017). Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. *Oncogene*, 36(32), 4585–4596. <https://doi.org/10.1038/onc.2017.76>.
- Jemal, A., Ward, E.M., Johnson, C.J., Cronin, K.A. , Ma, J., Ryerson, A.B. , Mariotto, A., Lake, A.J., Wilson, R., Sherman, R. L., Anderson, R. N., Henley, S. J., Kohler, B. A., Penberthy, L., Feuer, E. J., & Weir, H. K. (2017). Annual report to the nation on the status of cancer, 1975–2014, featuring survival. *J. Natl. Cancer Inst.*, 109(9), djkx030. <https://doi.org/10.1093/jnci/djkx030.e>
- Jevtić, P., & Levy, D. L. (2015). Nuclear size scaling during xenopus early development contributes to midblastula transition timing. *Current Biology*, 25(1), 45-52. <https://doi.org/10.1016/j.cub.2014.10.051>.
- Jordan, M. A., & Wilson, L. (2004). Microtubules as a target for anticancer drugs. In *Nature Reviews Cancer*, 4, 253–266. <https://doi.org/10.1038/nrc1317>.
- Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. *The Journal of Chemical Physics*, 79(2), 926–935. <https://doi.org/10.1063/1.445869>.
- Jyoti, K., Kaur, K., Pandey, R. S., Jain, U. K., Chandra, R., & Madan, J. (2015). Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: In vitro and in vivo studies. *Journal of Colloid and Interface Science*, 445, 219–230. <https://doi.org/10.1016/j.jcis.2014.12.092>.
- Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F., Jones, L. W. (1979). Establishment and characterization of a human prostatic carcinoma cell line (PC-3). *Investigative Urology*, 17:16–23.
- Kanyinda, B., Vanhaelen-Fastré, R., Vanhaelen, M., & Ottinger, R. (2002). Two new isochondodendrine-type alkaloids from the roots of Anisocycla jollyana. *Journal of Natural Products*, 60,(11), 1121-1124. <https://doi.org/10.1021/np970257j>.
- Kargbo, R. B. (2020). RAF Kinases in Cancer: A Moving Target and Degradation Therapy. *ACS Medicinal Chemistry Letters*, 11, (7), 1369-1370. <https://doi.org/10.1021/acsmmedchemlett.0c00299>.
- Kaur, G., Prabhakar, P. K., Lal, U. R., & Suttee, A. (2016). Phytochemical and biological analysis of Tinospora cordifolia. *International Journal of Toxicological and Pharmacological Research*, 8(4), 297–305.

- Kaur, H., Amini, M. H., Pranav Kumar Prabhakar, Singh, A., & Suttee, A. (2016). Phytochemical screening and antimicrobial activity of caesalpinia sappan L. Leaves. *International Journal of Pharmacognosy and Phytochemical Research*, 8(6), 1064–1069.
- Kayser, O., Kiderlen, A. F., & Croft, S. L. (2002). Natural products as potential antiparasitic drugs. *Studies in Natural Products Chemistry*, 26, 779–824. [https://doi.org/10.1016/S1572-5995\(02\)80019-9](https://doi.org/10.1016/S1572-5995(02)80019-9).
- Keeler, J. (2010). Understanding NMR Spectroscopy. In O. W. .Sørensen (Ed.), *Magnetic Resonance in Chemistry* (2nd ed.). Wiley. <https://doi.org/10.1002/mrc.1798>.
- Kessler, P. J. A. (1993). Flowering Plants. Dicotyledons Vol. II: Magnoliid, Hamamelid and Caryphyllid Families. In E. Kubitzki, K., Rohwer, J. G., Bittrich, V. (Ed.), *The Families and Genera of Vascular Plants*. Springer: Berlin, Heidelberg. <https://doi.org/10.1007/978-3-662-02899-5>.
- Khan, T., Ali, M., Khan, A., Nisar, P., Jan, S. A., Afzidi, S., & Shinwari, Z. K. (2019). Anticancer plants: A review of the active phytochemicals, applications in animal models, and regulatory aspects. *Biomolecules* 10(1), 47. <https://doi.org/10.3390/biom10010047>.
- Kikukawa, Y., Okuno, Y., Tatetsu, H., Nakamura, M., Harada, N., Ueno, S., Kamizaki, Y., Mitsuya, H., & Hata, H. (2008). Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a bisclaurine alkaloid. *International Journal of Oncology*, 33, 807–814. https://doi.org/10.3892/ijo_00000068.
- Kim, B. M., & Hong, S. H. (2011). Sequential caspase-2 and caspase-8 activation is essential for saikogenin a-induced apoptosis of human colon carcinoma cell lines. *Apoptosis*, 16, 184–197. <https://doi.org/10.1007/s10495-010-0557-x>.
- Kim, D. A., Jeon, Y. K., & Nam, M. J. (2012). Galangin induces apoptosis in gastric cancer cells via regulation of ubiquitin carboxy-terminal hydrolase isozyme L1 and glutathione S-transferase P. *Food and Chemical Toxicology*, 50(3–4), 684–688. <https://doi.org/10.1016/j.fct.2011.11.039>.
- Kim, J., Gripenberg, S., Karonen, M., & Salminen, J. P. (2021). Seed tannin composition of tropical plants. *Phytochemistry*, 187, 112750. <https://doi.org/10.1016/j.phytochem.2021.112750>.
- Kimman, M., Norman, R., Jan, S., Kingston, D., Woodward, M. (2012). The burden of cancer in member countries of the Association of Southeast Asian Nations (ASEAN). *Asian Pacific Journal of Cancer Prevention*, 13(2), 411-420. <https://doi.org/10.7314/apjcp.2012.13.2.411>.
- Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. *Nature Reviews Drug Discovery*, 3(11), 935-49. <https://doi.org/10.1038/nrd1549>.

- Knudsen, E. S., O'Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2016). Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. *Gastroenterology*, 150(1), 48–63. <https://doi.org/10.1053/j.gastro.2015.08.056>.
- Koch, A., Tamez, P., Pezzuto, J., & Soejarto, D. (2005). Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. *Journal of Ethnopharmacology*, 101, 95–99. <https://doi.org/10.1016/j.jep.2005.03.011>.
- Koshlan, T. V., & Kulikov, K. G. (2020). Analysis of Electrostatic Interactions of Amino Acid Residues by the Example of Formation of a Nap1–Nap1 Dimer. *Technical Physics*, 65, 333–339. <https://doi.org/10.1134/S1063784220030123>.
- Kotsakis, A., Matikas, A., Koinis, F., Kentepozidis, N., Varthalitis, I. I., Karavassilis, V., Samantas, E. P., Katsaounis, P., Dermitzaki, E. K., Hatzidakis, D., Mavroudis, D., & Georgoulias, V. (2016). A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. *British Journal of Cancer*, 115(7), 784–788. <https://doi.org/10.1038/bjc.2016.281>.
- Koutova, D., Kulhava, M., Havelek, R., Majorosova, M., Královec, K., Habartova, K., Hošťálková, A., Opletal, L., Cahlikova, L., & Řezáčová, M. (2020). Bersavine: A novel bisbenzylisoquinoline alkaloid with cytotoxic, antiproliferative and apoptosis-inducing effects on human leukemic cells. *Molecules*, 25(4), 964. <https://doi.org/10.3390/molecules25040964>.
- Krall, A. S., Xu, S., Graeber, T. G., Braas, D., & Christofk, H. R. (2016). Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. *Nature Communications*, 7, 11457. <https://doi.org/10.1038/ncomms11457>.
- Krishnamurthi K. (2000). Screening of natural products for anticancer and antidiabetic properties. *Health Administrator*, 20, 69–75.
- Kruczynski, A., Barret J-M., Etievant, C., Colpaert, F., Fahy, J., & Hill, B. T. (1998). Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. *Biochemical Pharmacology*, 55:635 – 648.
- Krvavych, A. S., Konechna, R. T., Petrina, R. O., Kyrka, M. S., Zayarnuk, N. L., Gulko, R. M., Stadnytska, N. E., & Novikov, V. P. (2014). Phytochemical research of plant extracts and use in vitro culture in order to preserve rare wild species Gladiolus imbricatus. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 5(1), 240–246.
- Kuhlman, B., & Bradley, P. (2019). Advances in protein structure prediction and design. *Nature Reviews Molecular Cell Biology*, 20, 681–697. <https://doi.org/10.1038/s41580-019-0163-x>.
- Kullmann, M. K., Podmirseg, S. R., Roilo, M., & Hengst, L. (2020). The CDK inhibitor p57Kip2 enhances the activity of the transcriptional coactivator FHL2. *Scientific Reports*, 10, 7140. <https://doi.org/10.1038/s41598-020-62641-4>.

- Kunle, O. O. (2000). The production of Pharmaceuticals from medical plants and their products. *Nig. J. of Nat. Prod. and Medicine*, 4, 9–12. <https://doi.org/10.4314/njnpm.v4i1.11730>.
- Kuroda H, Nakazawa S, Katajiri K, Shiratori O, Kozuka M. (1976). Antitumour effect of benzylisoquinoline alkaloid. *Chemistry Pharm. Bull (Tokyo)* 24(10), 2413-2420. <https://doi.org/10.1248/cpb.24.2413>
- Kuruppu, A. I., Paranagama, P., & Goonasekara, C. L. (2019). Medicinal plants commonly used against cancer in traditional medicine formulae in Sri Lanka. *Saudi Pharmaceutical Journal* 27(4), 565–573. <https://doi.org/10.1016/j.jps.2019.02.004>.
- Lalla, J. K., Hamrapurkar, P. D., & Mukherjee, S. A. (2004). Estimation of the saussureine content of root powder and a tablet formulation prepared from Saussurea lappa. *Journal of Planar Chromatography - Modern TLC*, 17(1), 36–39. <https://doi.org/10.1556/JPC.17.2004.1.8>.
- Lee, J. H., Kang, G. H., Kim, K. C., Kim, K. M., Park, D. Il, Choi, B. T., Kang, H. S., Lee, Y. T., & Choi, Y. H. (2002). Tetrrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells. *International Journal of Oncology*, 21(6), 1239–1244. <https://doi.org/10.3892/ijo.21.6.1239>.
- Lee M. H., Reynisdottir I., Massagué, J. (1995). Cloning of p57kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. . . *Genes Development*, 9, 639–649. <https://doi.org/10.1101/gad.9.6.639>.
- Lee, W. L., Huang, J. Y., & Shyur, L. F. (2013). Phytoagents for cancer management: Regulation of nucleic acid oxidation, ROS, and related mechanisms. *Oxidative Medicine and Cellular Longevity*, 2013, 925804. <https://doi.org/10.1155/2013/925804>.
- Lemke, J., Scheele, J., Kapapa, T., Wirtz, C. R., Henne-Bruns, D., & Kornmann, M. (2013). Brain Metastasis in Pancreatic Cancer. *International Journal of Molecular Sciences*, 14(2), 4163–4173. <https://doi.org/10.3390/ijms14024163>.
- Lengauer, T., & Rarey, M. (1996). Computational methods for biomolecular docking. *Current Opinion in Structural Biology*, . . 6(3), 402–406. [https://doi.org/10.1016/S0959-440X\(96\)80061-3](https://doi.org/10.1016/S0959-440X(96)80061-3).
- Leone, A., Spada, A., Battezzati, A., Schiraldi, A., Aristil, J., & Bertoli, S. (2015). Cultivation, genetic, ethnopharmacology, phytochemistry and pharmacology of *Moringa oleifera* leaves: An overview. *International Journal of Molecular Sciences* 16, 12791–12835. <https://doi.org/10.3390/ijms160612791>.
- Li, F., Jiang, T., Li, Q., & Ling, X. (2017). Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer? *American Journal of Cancer Research*, 7(12), 2350–2394.

- Li, G. B., Yang, L. L., Wang, W. J., Li, L. L., & Yang, S. Y. (2013). ID-score: A new empirical scoring function based on a comprehensive set of descriptors related to protein-ligand interactions. *Journal of Chemical Information and Modeling*, 53(3), 592–600. <https://doi.org/10.1021/ci300493w>.
- Li, X., Su, B., Liu, R., Wu, D., & He, D. (2011). Tetrandrine induces apoptosis and triggers caspase cascade in human bladder cancer cells. *Journal of Surgical Research*, 166(1), e45-51. <https://doi.org/10.1016/j.jss.2010.10.034>.
- Lichota, A., & Gwozdzinski, K. (2018). Anticancer Activity of Natural Compounds from Plant and Marine Environment. *International Journal of Molecular Sciences*, 19(11), 3533. <https://doi.org/10.3390/ijms19113533>.
- Lifongo, L. L., Simoben, C. V., Ntie-Kang, F., Babiaka, S. B., & Judson, P. N. (2014). A Bioactivity Versus Ethnobotanical Survey of Medicinal Plants from Nigeria, West Africa. *Natural Products and Bioprospecting*, 4(1), 1-19. <https://doi.org/10.1007/s13659-014-0005-7>.
- Lin, J., & Arlinghaus, R. (2008). Activated c-Abl tyrosine kinase in malignant solid tumors. *Oncogene*, 27, 4385–4391. <https://doi.org/10.1038/onc.2008.86>.
- Lin, S-S., Fan, W., Sun, L., Li, F. F., Zhao, R. P., Zhang, L. Y., Yu, B. Y., & Yuan, S. T. (2014). The saponin DT-13 inhibits gastric cancer cell migration through down-regulation of CCR5-CCL5 axis. *Chinese Journal of Natural Medicines*, 14 12(11), 833-40. [https://doi.org/10.1016/S1875-5364\(14\)60125-4](https://doi.org/10.1016/S1875-5364(14)60125-4).
- Linnaeus, C. (1753). Species Plantarum. In *Taxon* (1st ed.). Laurentius Salvius, Stockholm. <https://doi.org/10.2307/1217337>.
- Lins, S., Nanthakumar, R., & Arumugasamy, K. (2016). Phytochemical analysis and antimicrobial efficacy of a traditionally important medicinal plant - *Tiliacora acuminata* (Lam.) F. Thoms. (Menispermaceae). *Journal of Medicinal Plants Studies.*, 4(6), 18-22.
- Liu, H., Chang, D. W., & Yang, X. (2005). Interdimer processing and linearity of procaspase-3 activation. A unifying mechanism for the activation of initiator and effector caspases. *Journal of Biological Chemistry*, 280(12), 11578–11582. <https://doi.org/10.1074/jbc.M414385200>.
- Loconte, H. (1993). In *Flowering Plants—Dicotyledons: Magnoliid, Hamamelid and Caryophyllid Families* (E. Kubitzki, K., Rohwer, J. G., Bittrich, V. (ed.)). Springer: Berlin, Heidelberg.
- Lopes-Martins, R. A., Pegoraro, D. H., Woisky, R., Penna, S. C., & Sertié, J. A. A. (2002). The anti-inflammatory and analgesic effects of a crude extract of *Petiveria alliacea* L. (Phytolaccaceae). *Phytomedicine: international journal of phytotherapy and phytopharmacology*, 9(3), 245–248. <https://doi.org/10.1078/0944-7113-00118>.

- Lopes, A. P., Bagatela, B. S., Rosa, P. C. P., Nanayakkara, D. N. P., Carlos Tavares Carvalho, J., Maistro, E. L., Bastos, J. K., & Perazzo, F. F. (2013). Antioxidant and cytotoxic effects of crude extract, fractions and 4-nerolidylcathecol from aerial parts of pothomorphe umbellata L. (Piperaceae). *BioMed Research International*, 2013, 206581. <https://doi.org/10.1155/2013/206581>.
- Lopez-Vallejo, F., Caulfield, T., Martinez-Mayorga, K., A. Julianotti, M., Nefzi, A., A. Houghten, R., & L. Medina-Franco, J. (2011). Integrating Virtual Screening and Combinatorial Chemistry for Accelerated Drug Discovery. *Combinatorial Chemistry & High Throughput Screening*, 14, 475–487. <https://doi.org/10.2174/138620711795767866>.
- Lu, J. (2015). Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. *Journal of Hematology and Oncology*, 8(1), 98. <https://doi.org/10.1186/s13045-015-0194-5>.
- Lu, L., Zhao, Z., Liu, L., Gong, W., & Dong, J. (2018). Combination of baicalein and docetaxel additively inhibits the growth of non-small cell lung cancer in vivo. *Traditional Medicine and Modern Medicine*, 01(3), 213–218. <https://doi.org/10.1142/s2575900018500131>.
- Luz, D. A., Pinheiro, A. M., Silva, M. L., Monteiro, M. C., Prediger, R. D., Ferraz Maia, C. S., & Fontes-Júnior, E. A. (2016). Ethnobotany, phytochemistry and neuropharmacological effects of Petiveria alliacea L. (Phytolaccaceae): A review. *Journal of Ethnopharmacology* 185, 182–201. <https://doi.org/10.1016/j.jep.2016.02.053>.
- MacKenzie, S. H., & Clark, A. C. (2012). Death by caspase dimerization. In Matthews J.M (Ed.), *Advances in Experimental Medicine and Biology*. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3229-6_4.
- Majekodunmi, S. O. (2015). Review of extraction of medicinal plants for pharmaceutical research. *Merit Research Journal of Medicine and Medical Sciences*, 3(11), 521–527.
- Malviya, N., & Malviya, S. (2017). Bioassay guided fractionation-an emerging technique influence the isolation, identification and characterization of lead phytomolecules. *International Journal of Hospital Pharmacy*, 2, 5. <https://doi.org/10.28933/ijhp-2017-07-0901>.
- Martin, S. K., & Kyriianou, N. (2015). Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. *Advances in Cancer Research*, 127, 123-158. <https://doi.org/10.1016/bs.acr.2015.03.001>.
- Martínez, L. (2015). Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis. *PLoS ONE*, 10(3), e0119264. <https://doi.org/10.1371/journal.pone.0119264>.

- Martino, E., Casamassima, G., Castiglione, S., Cellupica, E., Pantalone, S., Papagni, F., Rui, M., Siciliano, A. M., & Collina, S. (2018). Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead. *Bioorganic and Medicinal Chemistry Letters*, 28(17), 2816-2826. <https://doi.org/10.1016/j.bmcl.2018.06.044>.
- Matata, D. Z., Ngassapa, O. D., Machumi, F., & Moshi, M. J. (2018). Screening of Plants Used as Traditional Anticancer Remedies in Mkuranga and Same Districts, Tanzania, Using Brine Shrimp Toxicity Bioassay. *Evidence-Based Complementary and Alternative Medicine*, 2018, 3034612. <https://doi.org/10.1155/2018/3034612>.
- Mateescu, G. D., & Valeriu, A. (1993). 2D NMR Density Matrix and Product Operator Treatment. *Journal of Chemical Education*, 70, 6, A17. <https://doi.org/10.1021/ed070pa172.3>.
- Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., & Elledge, S. J. (1995). P57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. *Genes and Development*, 9(6), 650–662. <https://doi.org/10.1101/gad.9.6.650>.
- Maya-Mendoza, A., Moudry, P., Merchut-Maya, J. M., Lee, M., Strauss, R., & Bartek, J. (2018). High speed of fork progression induces DNA replication stress and genomic instability. *Nature*, 559(7713), 279–284. <https://doi.org/10.1038/s41586-018-0261-5>.
- Meegan, M. J., & O'Boyle, N. M. (2019). Special Issue “Anticancer Drugs.” *Pharmaceuticals*, 12(3), 134.
- Mena-Ulecia, K., Tiznado, W., & Caballero, J. (2015). Study of the differential activity of thrombin inhibitors using docking, QSAR, molecular dynamics, and MM-GBSA. *PLoS ONE*, 10, e0142774. <https://doi.org/10.1371/journal.pone.0142774>.
- Meng, X-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2012). Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. *Current Computer Aided-Drug Design*, 7, 146–157. <https://doi.org/10.2174/157340911795677602>.
- Meza, J. C. (2010). Steepest descent. *Wiley Interdisciplinary Reviews: Computational Statistics*, 2(6), 719–722. <https://doi.org/10.1002/wics.117>.
- Michelena, J., Lezaja, A., Teloni, F., Schmid, T., Imhof, R., & Altmeyer, M. (2018). Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. *Nature Communications*, 9(1), 2678. <https://doi.org/10.1038/s41467-018-05031-9>.
- Millimouno, F. M., Dong, J., Yang, L., Li, J., & Li, X. (2014). Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. *Cancer Prevention Research*, 7(11), 1081–107. <https://doi.org/10.1158/1940-6207.CAPR-14-0136>.

- Min, A., & Im, S. A. (2020). PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. *Cancers*, 12(2), 394. <https://doi.org/10.3390/cancers12020394>.
- Modi, S. J., & Kulkarni, V. M. (2019). Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective. *Medicine in Drug Discovery*, 2, 100009. <https://doi.org/10.1016/j.medidd.2019.100009>.
- Mohammed, S., Van Buren, G., & Fisher, W. E. (2014). Pancreatic cancer: Advances in treatment. *World Journal of Gastroenterology*, 20(28), 9354–9360. <https://doi.org/10.3748/wjg.v20.i28.9354>.
- Molina-Montes, E., Sánchez, M. J., Zamora-Ros, R., Bueno-de-Mesquita, H. B., Wark, P. A., Obon-Santacana, M., Kühn, T., Katzke, V., Travis, R. C., Ye, W., Sund, M., Naccarati, A., Mattiello, A., Krogh, V., Martorana, C., Masala, G., Amiano, P., Huerta, J. M., Barricarte, A., ... Duell, E. J. (2016). Flavonoid and lignan intake and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort. *International Journal of Cancer*, 139, 1480–1492. <https://doi.org/10.1002/ijc.30190>.
- Moo, T. A., Sanford, R., Dang, C., & Morrow, M. (2016). Overview of Breast Cancer Therapy. *PET Clinics*, 13(3), 339–354. [10.1016/j.cpet.2018.02.006](https://doi.org/10.1016/j.cpet.2018.02.006).
- Morales, J. C., Li, L., Fattah, F. J., Dong, Y., Bey, E. A., Patel, M., Gao, J., & Boothman, D. A. (2014). Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. *Critical Reviews in Eukaryotic Gene Expression*, 24(1), 15–28. <https://doi.org/10.1615/CritRevEukaryotGeneExpr.2013006875>.
- Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *Journal of Immunological Methods*, 65(1–2), 55–63. [https://doi.org/10.1016/0022-1759\(83\)90303-4](https://doi.org/10.1016/0022-1759(83)90303-4).
- Muegge, I. (2006). PMF scoring revisited. *Journal of Medicinal Chemistry*, 49, 5895–5902. <https://doi.org/10.1021/jm050038s>.
- Nagai, H., & Kim, Y. H. (2017). Cancer prevention from the perspective of global cancer burden patterns. *Journal of Thoracic Disease*, 9(3), 448–451. <https://doi.org/10.21037/jtd.2017.02.75>.
- Nakamura, K., Tsuchiya, S., Sugimoto, Y., Sugimura, Y., & Yamada, Y. (1992). Histamine release inhibition activity of bisbenzylisoquinoline alkaloids. *Planta Medica*, 58(6), 505–508. <https://doi.org/10.1055/s-2006-961536>.
- Nandini D. B. (2017). Cancer Cell Nucleus: An Insight. *Journal of Molecular Biomarkers & Diagnosis*, S2, 026. <https://doi.org/10.4172/2155-9929.s2-026>.
- Nnamudi, A. C., Ebohon, E. & Etim, O. E. (2020). Phytochemical Constituents, Antinutritional Factors and In Vitro Antioxidant Potential of *Synclisia scabrida* Root Extracts. *Biokemistri*, 32(3), 165 – 175.

- National Population Commission of Nigeria. (2016). National Population Estimates. *National Population Commission and National Bureau of Statistics Estimates*.
- Newcomb, E. W. (2004). Flavopiridol: Pleiotropic biological effects enhance its anti-cancer activity. *Anti-Cancer Drugs*, 15(5), 411–419. <https://doi.org/10.1097/01.cad.0000127332.06439.47>.
- Newman, D. J., & Cragg, G. M. (2016). Natural Products as Sources of New Drugs from 1981 to 2014. *Journal of Natural Products*, 79,(3): 629–661. <https://doi.org/10.1021/acs.jnatprod.5b01055>.
- Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004). Protein Kinase Inhibitors: Insights into Drug Design from Structure. *Science*, 303, 1800–1805. <https://doi.org/10.1126/science.1095920>.
- Nor'ashikin, S., Ruziyati, T., Mardiana, S. (2012). *Analytical Separation Methods Laboratory Guide* (2nd edition).
- Nordin, N., Majid, N. A., Hashim, N. M., Rahman, M. A., Hassan, Z., & Ali, H. M. (2015). Liriodenine, an aporphine alkaloid from *Enicosanthellum pulchrum*, inhibits proliferation of human ovarian cancer cells through induction of apoptosis via the mitochondrial signaling pathway and blocking cell cycle progression. *Drug Design, Development and Therapy*, 9, 1437–1448. <https://doi.org/10.2147/DDDT.S77727>.
- Nurgali, K., Jagoe, R. T., & Abalo, R. (2018). Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? *Frontiers in Pharmacology*, 9: 245. <https://doi.org/10.3389/fphar.2018.00245>.
- Nwaiwu, J. I., & Akah, P. A. (1986). Anticonvulsant activity of the volatile oil from the fruit of *Etrapleura tetraptera*. *Journal of Ethnopharmacology*, 18(2), 103–107. [https://doi.org/10.1016/0378-8741\(86\)90023-1](https://doi.org/10.1016/0378-8741(86)90023-1).
- Obi, E., Emeh, J. K., Orisakwe, O. E., Afonne, O. J., Ilondu, N. A., & Agbasi, P. U. (2000). Investigation of the biochemical evidence for the antiulcerogenic activity of *Synclisia scabrida*. *Indian Journal of Pharmacology*, 32, 381-383.
- Obiorah, C. C., & Nwafor, C. C. (2019). Cancer mortality in the Niger Delta Region of Nigeria: A case study of the University of Port Harcourt Teaching Hospital. *Nigerian Medical Journal.*, 60(5), 268–272. https://doi.org/doi:10.4103/nmj.NMJ_15_19.
- Ochwang'i, D. O., Kimwele, C. N., Oduma, J. A., Gathumbi, P. K., Mbaria, J. M., & Kiama, S. G. (2014). Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. *Journal of Ethnopharmacology*, 151(3), 1040–1055. <https://doi.org/10.1016/j.jep.2013.11.051>.
- Ogunwobi, O. O., Mahmood, F., & Akingboye, A. (2020). Biomarkers in colorectal cancer: Current research and future prospects. *International Journal of Molecular Sciences*, 21(15), 5311. <https://doi.org/10.3390/ijms21155311>.

- Ohashi, K., Hosoya, T., Takahashi, K., Hing, H., & Mizuno, K. (2000). A Drosophila homolog of LIM-kinase phosphorylates cofilin and induces actin cytoskeletal reorganization. *Biochemical and Biophysical Research Communications*, 276, (3), 1178–1185.
- Ohiri, F.C., Verpoorte, R. & Baerheim Svendsen, A. (1983). Cycleanine N-oxide, a new alkaloid from *Synclisia scabrida*. *Planta Medica*, 47(2), 87–89. <https://doi.org/10.1055/s-2007-969958>.
- Okafor, J.I., Eze, E. A., & Njoku., O. U. (2001). Antifungal activities of the Leaves of *Baphia nitida*, *Cassia alata*, *Ficus exasperata* and *Gassypium arboreum*. *Nig. J. of Nat. Prod. and Medicine.*, 5, 59–60. <https://doi.org/10.4314/njnpm.v5i1.11728>.
- Okoli, S., & Iroegbu, C. U. (2005). *In vitro antibacterial activity of Synclisia scabrida whole root extracts*. *African Journal of Biotechnology*, 4(9), 946–952.
- Okuda, T.; Yoshida, T.; & Hatano, T. (1992). Antioxidant effects of tannins and related polyphenols. *ACS Symposium Series; American Chemical Society*, 504, <https://doi.org/10.3390/molecules16032191>.
- Olomieja, A. O., Olanrewaju, I. O., Ayo-Ajayi, J. I., Jolayemi, G. E., Daniel, U. O., & Mordi, R. C. (2021). Potency of the Leaf, Stem and Root Extracts of Petiveria alliacea Against Selected Microorganisms. *IOP Conference Series: Materials Science and Engineering*, 1107(2021), 01205. <https://doi.org/10.1088/1757-899x/1107/1/012051>.
- Olsen, M. M., & Naseman, R. W. (2019). Chemotherapy. In (Olsen, M.M., LeFebvre K.B., Brassil, K.J., eds.) *Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice*. Pittsburgh, PA: Oncology Nursing Society, 2019, 61–90.
- Olusegun, A. F., & Ehis, O. C. (2010). Hyperendemicity of Onchocerciasis in ovia northeast local government area, Edo State, Nigeria. *Malaysian Journal of Medical Sciences*, 17(4), 20–24.
- Omara, T., Kiprop, A. K., Ramkat, R. C., Cherutoi, J., Kagoya, S., Nyangena, M. D., Tebo, T. A., Nteziyaremye, P., Karanja, L. N., Jepchirchir, A., Maiyo, A., Kiptui, B. J., Mbabazi, I., Nakiguli, C. K., Nakabuye, B. V., & Koske, M. C. (2020). Medicinal Plants Used in Traditional Management of Cancer in Uganda: A Review of Ethnobotanical Surveys, Phytochemistry, and Anticancer Studies. *Evidence-based Complementary and Alternative Medicine*, 2020, 3529081. <https://doi.org/10.1155/2020/3529081>.
- Omona, J. (2013). Sampling in Qualitative Research: Improving the Quality of Research Outcomes in Higher Education. *Makerere Journal of Higher Education*, 4, 169–185. <https://doi.org/10.4314/majohe.v4i2.4>.

- Onwudiwe, T., Ughachukwu, P., Unekwe, P., & Ogamba, J. (2012). Evaluation of antiulcer properties of ethanolic and hot aqueous stem extracts of *Synclisia scabrida* on experimentally induced ulcer models in albino mice. *Annals of Medical and Health Sciences Research*, 2(2), 134-139. <https://doi.org/10.4103/2141-9248.105660>.
- Ormerod, M. G. (1999). Flow Cytometry: A Practical Approach. In *Flow Cytometry: A Practical Approach*. IRL Press at Oxford University Press.
- Ortiz, R. D. C., Kellogg, E. A., & Van Der Werff, H. (2007). Molecular phylogeny of the moonseed family (Menispermaceae): Implications for morphological diversification. *American Journal of Botany*, 94(8), 1425–1438. <https://doi.org/10.3732/ajb.94.8.1425>.
- Osawaru M.E., Ogwu M.C. (2021) Plants and Plant Products in Local Markets Within Benin City and Environs. In: Leal Filho W., Oguge N., Ayal D., Adeleke L., da Silva I. (eds) African Handbook of Climate Change Adaptation. Springer, Cham. https://doi.org/10.1007/978-3-030-45106-6_159
- Oteng, M. S., Asafo-Agyei, T., Archer, M.-A., Atta-Adjei Junior, P., Boamah, D., Kumadoh, D., Appiah, A., Ocloo, A., Duah Boakye, Y., & Agyare, C. (2019). Medicinal Plants for Treatment of Prevalent Diseases. In S. Perveen & A. Al-Taweel (Eds), *Pharmacognosy - Medicinal Plants*. IntechOpen. <https://doi.org/10.5772/intechopen.82049>.
- Pan, C., Liu, H., Robins, E., Song, W., Liu, D., Li, Z., & Zheng, L. (2020). Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. *Journal of Hematology & Oncology*, 13, 29. <https://doi.org/10.1186/s13045-020-00862-w>.
- Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016). Flavonoids: An overview. *Journal of Nutritional Science*, 5, e47. <https://doi.org/10.1017/jns.2016.41>.
- Pandey, A., & Tripathi, S. (2014). Concept of standardization, extraction and pre phytochemical screening strategies for herbal drug. *Journal of Pharmacognosy and Phytochemistry*, 2(5), 115–119.
- Panigrahi, G. K., Praharaj, P. P., Kittaka, H., Mridha, A. R., Black, O. M., Singh, R., Mercer, R., van Bokhoven, A., Torkko, K. C., Agarwal, C., Agarwal, R., Abd Elmageed, Z. Y., Yadav, H., Mishra, S. K., & Deep, G. (2019). Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. *Cancer Medicine*, 8(3), 1110–1123. <https://doi.org/10.1002/cam4.1885>.
- Panka, D. J., Atkins, M. B., & Mier, J. W. (2006). Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. *Clinical Cancer Research*, 12(7 Pt 2), 2371s-2375s. <https://doi.org/10.1158/1078-0432.CCR-05-2539>.

- Pérez-Labrada, K., Brouard, I., Estévez, S., Marrero, M. T., Estévez, F., Bermejo, J., & Rivera, D. G. (2012). New insights into the structure-cytotoxicity relationship of spirostan saponins and related glycosides. *Bioorganic and Medicinal Chemistry*, 20(8), 2690–2700. <https://doi.org/10.1016/j.bmc.2012.02.026>.
- Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018). CDK4/6 inhibition in breast cancer: current practice and future directions. *Therapeutic Advances in Medical Oncology*, 10, 1758835918786451. <https://doi.org/10.1177/1758835918786451>.
- Petric, R. C., Braicu, C., Raduly, L., Zanoaga, O., Dragos, N., Monroig, P., Dumitrescu, D., & Berindan-Neagoe, I. (2015). Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers. *Oncotargets and Therapy*, 2015, 2053–2066. <https://doi.org/10.2147/OTT.S83597>.
- Phillips, O. (1991). The ethnobotany and economic botany of tropical vines. In F. E. P. & H. A. Mooney (Eds.), *The Biology of Vines*, 427–469. Cambridge University Press.,
- Pinzi, L., Lherbet, C., Baltas, M., Pellati, F., & Rastelli, G. (2019). In silico repositioning of cannabigerol as a novel inhibitor of the enoyl acyl carrier protein (ACP) reductase (INHA). *Molecules*, 24, 2567. <https://doi.org/10.3390/molecules24142567>.
- Pissurlenkar, R. R. S., Shaikh, M. S., Iyer, R. P., & Coutinho, E. C. (2009). Molecular mechanics force fields and their applications in drug design. *Anti-Infective Agents in Medicinal Chemistry*, 8, 128. <https://doi.org/10.2174/187152109787846088>.
- Pledgie-Tracy, A., Sobolewski, M. D., & Davidson, N. E. (2007). Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. *Molecular Cancer Therapeutics*, 6(3), 1013–1021. <https://doi.org/10.1158/1535-7163.MCT-06-0494>.
- Poornima, P., Weng, C. F., & Padma, V. V. (2014). Neferine, an alkaloid from lotus seed embryo, inhibits human lung cancer cell growth by MAPK activation and cell cycle arrest. *BioFactors*, 40, 121–131. <https://doi.org/10.1002/biof.1115>.
- Popoola, A. O., Omodele, F. O., Oludara, M. A., Ibrahim, N. O., Igwilo, A. I., Makajuola, S. B. L. (2013). Prevalence and pattern of cancers among adults attending a tertiary health institution in Lagos, Nigeria. *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, 6(3), 68–73.
- Porta, R., Borea, R., Coelho, A., Khan, S., Araújo, A., Reclusa, P., Franchina, T., Van Der Steen, N., Van Dam, P., Ferri, J., Sirera, R., Naing, A., Hong, D., & Rolfo, C. (2017). FGFR a promising druggable target in cancer: Molecular biology and new drugs. *Critical Reviews in Oncology/Hematology*, 113, 256–267. <https://doi.org/10.1016/j.critrevonc.2017.02.018>.
- Pulido-Moran, M., Moreno-Fernandez, J., Ramirez-Tortosa, C., & Ramirez-Tortosa, M. C. (2016). Curcumin and health. *Molecules*, 21(3), 264.

<https://doi.org/10.3390/molecules21030264>.

- Qadir, M. I., Naqvi, S. T. Q., & Muhammad, S. A. (2016). Curcumin: A polyphenol with molecular targets for cancer control. *Asian Pacific Journal of Cancer Prevention*, 17(6), 2735–2739.
- Qi, X., Wang, L., & Du, F. (2010). Novel small molecules relieve prothymosin α -mediated inhibition of apoptosis formation by blocking its interaction with Apaf-1. *Biochemistry*, 49(9), 1923–1930. <https://doi.org/10.1021/bi9022329>.
- Queitilane de, S. S., Fernanda, M. B., Amaro, C. R., Marina, M. P., Maria, R. G. V., Milton, M. K., & Rodrigo, R. O. (2016). Phytochemical analysis and cytotoxic activity of Petiveria alliacea (Phytolaccaceae). *International Journal of Science.*, 5, 53–58.
- Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Research*, 74(11), 2913–2921. <https://doi.org/10.1158/0008-5472.CAN-14-0155>.
- Rajeswara, R. B. R., Singh, K., Sastry, K. P., Singh, C. P., Kothari, S.K., Rajput, D. K., Bhattacharya, A. K. (2007). Cultivation Technology for Economically Important Medicinal Plants. In Reddy K. J., Bahadur B., Bhadraiah B., & Rao M. L. N. (Eds.), *Advances in Medicinal Plants*, 112–122. University Press; Hyderabad.
- Ramírez, D., & Caballero, J. (2018). Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data? *Molecules*, 23(5), 1038. <https://doi.org/10.3390/molecules23051038>.
- Ramsey, S., Blough, D., Kirchhoff, A., Kreizenbeck, K., Fedorenko, C., Snell, K., Newcomb, P., Hollingworth, W., & Overstreet, K. (2013). Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. *Health Affairs*, 32(6), 114. <https://doi.org/10.1377/hlthaff.2012.1263>.
- Ranjan, D., Chen, C., Johnston, T. D., Jeon, H., & Nagabhushan, M. (2004). Curcumin inhibits mitogen stimulated lymphocyte proliferation, NF κ B activation, and IL-2 signaling. *Journal of Surgical Research*, 121(2), 171–177. <https://doi.org/10.1016/j.jss.2004.04.004>.
- Raphael, E. C. (2011). Traditional medicine in Nigeria: Current status and the future. *Research Journal of Pharmacology*, 5(6), 90–94. <https://doi.org/10.3923/rjpharm.2011.90.94>.
- Rawla, P., Sunkara, T., & Gaduputi, V. (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World Journal of Oncology*, 10(1), 10–27. Rawla, P., Sunkara, T., & Gaduputi, V. (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World journal of oncology*, 10(1), 10–27. <https://doi.org/10.14740/wjon1166>

- Rawla, P. (2019). Epidemiology of Prostate Cancer. *World Journal of Oncology*, 10(2), 63–89. <https://doi.org/https://doi.org/10.14740/wjon1191>.
- Raza, H., & John, A. (2005). Green tea polyphenol epigallocatechin-3-gallate differentially modulates oxidative stress in PC12 cell compartments. *Toxicology and Applied Pharmacology*, 207, 212–220. <https://doi.org/10.1016/j.taap.2005.01.004>.
- Reale, G., Russo, G. I., Di Mauro, M., Regis, F., Campisi, D., Giudice, A. Lo, Marranzano, M., Ragusa, R., Castelli, T., Cimino, S., & Morgia, G. (2018). Association between dietary flavonoids intake and prostate cancer risk: A case-control study in Sicily. *Complementary Therapies in Medicine*, 39, 14–18. <https://doi.org/10.1016/j.ctim.2018.05.002>.
- Reuveni, H., Livnah, N., Geiger, T., Klein, S., Ohne, O., Cohen, I., Benhar, M., Gellerman, G., & Levitzki, A. (2002). Toward a PKB inhibitor: Modification of a selective PKA inhibitor by rational design. *Biochemistry*, 41, 10304–10314. <https://doi.org/10.1021/bi0202530>.
- Revathidevi, S., & Munirajan, A. K. (2019). Akt in cancer: Mediator and more. *Seminars in Cancer Biology*, 59, 80–91. <https://doi.org/10.1016/j.semcan.2019.06.002>.
- Rezk, A., Al-Hashimi, A., John, W., Schepker, H., Ullrich, M. S., & Brix, K. (2015). Assessment of cytotoxicity exerted by leaf extracts from plants of the genus Rhododendron towards epidermal keratinocytes and intestine epithelial cells. *BMC Complementary and Alternative Medicine*, 15, 364. <https://doi.org/10.1186/s12906-015-0860-8>.
- Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S. Y., Robell, K., Kahana, J. A., Geske, R. S., Kleymenova, E. V., Choudhry, A. E., Lai, Z., Leber, J. D., Minthorn, E. A., Strum, S. L., Wood, E. R., ... Kumar, R. (2008). Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. *Cancer Research*, 68, 2366–2374. <https://doi.org/10.1158/0008-5472.CAN-07-5783>.
- Risinger, A. L., Giles, F. J., & Mooberry, S. L. (2009). Microtubule dynamics as a target in oncology. *Cancer Treatment Reviews*, 35, 255–261.
- Riss, T. L., Moravec, R. A., Niles, A. L., Benink, H. A., Worzella, T. J., & Minor, L. (2004). Cell Viability Assays. 2013 May 1 [updated 2016 Jul 1]. In: Markossian, S., Grossman, A., Brimacombe, K., Arkin, M., Auld, D., Austin, C. P., Baell, J., Chung, T. D. Y., Coussens, N. P., Dahlin, J. L., Devanarayanan, V., Foley, T. L., Glicksman, M., Hall, M. D., Haas, J. V., Hoare, S. R. J., Inglese, J., Iversen, P. W., Kales, S. C., ... Xu, X. (eds.). *Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004*.
- Rocha, L. D., Maranho, L. T., & Preussler K. H., (2006). Stem and leaf structural organization of Petiveria alliacea L., Phytolaccaceae. *Brazilian Journal of*

Pharmacy, 87, 98-101.

- Rodríguez-García, C., Sánchez-Quesada, C., Toledo, E., Delgado-Rodríguez, M., & Gaforio, J. J. (2019). Naturally Lignan-Rich Foods: A Dietary Tool for Health Promotion? *Molecules (Basel, Switzerland)*, 24(5), 917. <https://doi.org/10.3390/molecules24050917>.
- Rofiee, M. S., Yusof, M. I. M., Abdul Hisam, E. E., Bannur, Z., Zakaria, Z. A., Somchit, M. N., Teh, L. K., & Salleh, M. Z. (2015). Isolating the metabolic pathways involved in the hepatoprotective effect of *Muntingia calabura* against CCl₄-induced liver injury using LC/MS Q-TOF. *Journal of Ethnopharmacology*, 166, 109–118. <https://doi.org/10.1016/j.jep.2015.03.016>.
- Rossari, F., Minutolo, F., & Orciuolo, E. (2018). Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy. *Journal of Hematology and Oncology*, 11, 84 (2018). <https://doi.org/10.1186/s13045-018-0624-2>.
- Rotich, B. (2019). Forest Conservation and Utilization in Embobut, Cherangani Hills, Kenya. *International Journal of Natural Resource Ecology and Management*, 4(1), 7–13. <https://doi.org/10.11648/j.ijnrem.20190401.12>.
- Rui, G., Silva, H. C., Carvalho, L., Botelho, M. F., & Motapinto, A. (2016). MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. *Scientific Reports*, 6: 21648.
- Said, R., & Tsimberidou, A. M. (2014). Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. *Expert Opinion on Drug Metabolism and Toxicology*, 10, 483–494. <https://doi.org/10.1517/17425255.2014.885016>.
- Sak, K. (2014). Cytotoxicity of dietary flavonoids on different human cancer types. *Pharmacognosy Reviews*, 8(16), 122–146. <https://doi.org/10.4103/0973-7847.134247>.
- Sharp, K.A. (2006) Electrostatic interactions in proteins. In: Rossmann M.G., & Arnold E. (eds) International Tables for Crystallography Volume F: Crystallography of biological macromolecules. *International Tables for Crystallography*, F, 553–557. Springer, Dordrecht. <https://doi.org/10.1107/97809553602060000712>.
- Salentin, S., Haupt, V. J., Daminelli, S., & Schroeder, M. (2014). Polypharmacology rescored: Protein-ligand interaction profiles for remote binding site similarity assessment. *Progress in Biophysics and Molecular Biology*, 116, 174–186. <https://doi.org/10.1016/j.pbiomolbio.2014.05.006>.
- Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Alexandre, A. M., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., Lescrinier, E., Marimuthu, P., Mirza, M. U., Mustafa, G., Nunes-Alves, A., Pantsar, T., Saadabadi, A., Singaravelu, K., & Vanmeert, M. (2021). Molecular dynamics simulations in drug discovery and pharmaceutical development.

- Processes*, 9: 71. <https://doi.org/10.3390/pr9010071>.
- Sameer, R., Nidhi, S., Tarun, V., Charan, S., & Jyoti, G. (2016). A review on naturally derived compounds for potential anticancer activity. *Indian Journal of Drugs*, 4(3), 75–86.
- Salomon-Ferrer, R., Götz, A. W., Poole, D., Le Grand, S., & Walker, R. C. (2013). Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh ewald. *Journal of Chemical Theory and Computation*, 9(9), 3878–3888. <https://doi.org/10.1021/ct400314y>.
- Saroya, A. S. (2011). Herbalism, phytochemistry and ethnopharmacology. In *Herbalism, Phytochemistry and Ethnopharmacology*. Science Publishers. <https://doi.org/10.1201/b10878>.
- Sasidharan, S., Chen, Y., Saravanan, D., Sundram, K. M., & Yoga Latha, L. (2011). Extraction, isolation and characterization of bioactive compounds from plants' extracts. *African Journal of Traditional, Complementary and Alternative Medicines*, 8, 1–10. <https://doi.org/10.4314/ajtcam.v8i1.60483>.
- Sathiyabalan, G., Paulpriya, K., Tresina, P. S., Muthukumarasamy, S., & Mohan, V. R. (2017). Pharmacognostical, Physicochemical and Phytochemical Standardization of Petiveria alliacea L. *International Journal of Pharmacognosy and Phytochemical Research*, 9(2), 233–241. <https://doi.org/10.25258/phyto.v9i2.8068>.
- Sawada, T., Fedorov, D. G., & Kitaura, K. (2010). Role of the key mutation in the selective binding of avian and human influenza hemagglutinin to sialosides revealed by quantum-mechanical calculations. *Journal of the American Chemical Society*, 132, 16862–16872. <https://doi.org/10.1021/ja105051e>.
- Sawah, E. Al, Marchion, D. C., Xiong, Y., Ramirez, I. J., Abbasi, F., Boac, B. M., Bush, S. H., Zgeib, N. B., McClung, E. C., Khulpateea, B. R., Berry, A., Hakam, A., Wenham, R. M., Lancaster, J. M., & Judson, P. L. (2015). The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest. *Journal of Cancer Research and Clinical Oncology*, 141, 237–242. <https://doi.org/10.1007/s00432-014-1797-x>.
- Saxty, G., Woodhead, S. J., Berdini, V., Davies, T. G., Verdonk, M. L., Wyatt, P. G., Boyle, R. G., Barford, D., Downham, R., Garrett, M. D., & Carr, R. A. (2007). Identification of inhibitors of protein kinase B using fragment-based lead discovery. *Journal of Medicinal Chemistry*, 50, 2293–2296. <https://doi.org/10.1021/jm070091b>.
- Scheinmann, F., Scriven, E. F. V., & Ogbeide, O. N. (1980a). Cycleanine from *Synclisia scabrida*: conformational information from the ^1H NMR spectrum at 300 MHz. *Phytochemistry*, 19(8), 1937–1940. [https://doi.org/10.1016/S0031-9422\(00\)83824-8](https://doi.org/10.1016/S0031-9422(00)83824-8).
- Scheinmann, F., Scriven, E. F. V., & Ogbeide, O. N. (1980b). Cycleanine from *Synclisia scabrida*: conformational information from the ^1H NMR spectrum at 300 MHz.

- Phytochemistry*, 19(8), 1837–1840. [https://doi.org/10.1016/S0031-9422\(00\)83824-8](https://doi.org/10.1016/S0031-9422(00)83824-8).
- Schelz, Z., Ocsovszki, I., Bózsity, N., Hohmann, J., & Zupkó, I. (2016). Antiproliferative effects of various furanoacridones isolated from *ruta graveolens* on human breast cancer cell lines. *Anticancer Research*, 36, 2751–2758.
- Schipper, J. L., MacKenzie, S. H., Sharma, A., & Clark, A. C. (2011). A bifunctional allosteric site in the dimer interface of procaspase-3. *Biophysical Chemistry*, 159(1), 100–109. <https://doi.org/10.1016/j.bpc.2011.05.013>.
- Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018). Controlled drug delivery vehicles for cancer treatment and their performance. *Signal Transduction and Targeted Therapy*, 3, 7. <https://doi.org/10.1038/s41392-017-0004-3>.
- Shah, U., Shah, R., Acharya, S., & Acharya, N. (2013a). Novel anticancer agents from plant sources. *Chinese Journal of Natural Medicines*, 11(1), 16–23. [https://doi.org/10.1016/S1875-5364\(13\)60002-3](https://doi.org/10.1016/S1875-5364(13)60002-3).
- Shah, U., Shah, R., Acharya, S., & Acharya, N. (2013b). Novel anticancer agents from plant sources. *Chinese Journal of Natural Medicines*, 11(1), 16–23. [https://doi.org/10.1016/S1875-5364\(13\)60002-3](https://doi.org/10.1016/S1875-5364(13)60002-3).
- Shani, Z., Keren, R., Renana, S., Reem, T., Prashant, K. G., & Dan T. M. (2021). Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro. *Journal of Chemical Information and Modeling*, 61(6), 2957–2966. DOI: 10.1021/acs.jcim.1c00263.
- Shankar, K., Mitra, K., & Rangesh, P. R. (2003). Irritable Colon (Grahani). In *Scientific Basis for Ayurvedic Therapies* (1st ed.).
- Sharanabasappa, G. K., Santosh, M. K., Shaila, D., Seetharam, Y. N., & Sanjeevarao, I. (2007). Phytochemical studies on *Bauhinia racemosa* Lam. *Bauhinia purpurea* Linn. and *Hardwickia binata* Roxb. *E-Journal of Chemistry*, 4, 21–31. <https://doi.org/10.1155/2007/874721>.
- Shosan, L. O., Fawibe, O. O., Ajiboye, A. A., Abeegunrin, T. A., & Agboola, D. A. (2014). Ethnobotanical Survey of Medicinal Plants Used in Curing Some Diseases in Infants in Abeokuta South Local Government Area of Ogun State, Nigeria. *American Journal of Plant Sciences*, 5, 3258–3268. <https://doi.org/10.4236/ajps.2014.521340>.
- Shrestha, P. M., & Dhillon, S. S. (2003). Medicinal plant diversity and use in the highlands of Dolakha district, Nepal. *Journal of Ethnopharmacology*, 86, 81–96. [https://doi.org/10.1016/S0378-8741\(03\)00051-5](https://doi.org/10.1016/S0378-8741(03)00051-5).
- Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer statistics, 2017. *CA: A Cancer Journal for Clinicians*, 67, 7–30. <https://doi.org/10.3322/caac.21387>.

- Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer statistics, 2015. *CA Cancer J Clin*, 67, 7–30. <https://doi.org/10.3322/caac.21254>.
- Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. *CA: A Cancer Journal for Clinicians*, 68(1), 7–30. <https://doi.org/10.3322/caac.21442>.
- Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. *CA: A Cancer Journal for Clinicians*, 70, 145–154. <https://doi.org/10.3322/caac.21590>.
- Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. *CA: A Cancer Journal for Clinicians*, 71(1), 7–33. <https://doi.org/10.3322/caac.21654>. Erratum in: CA Cancer J Clin. 2021 Jul;71(4):359.
- Slade, D. (2020). PARP and PARG inhibitors in cancer treatment. *Genes and Development*, 34, 360–394. <https://doi.org/10.1101/gad.334516.119>.
- Society, A. C. (2021). How Common Is Breast Cancer? In *American Cancer Society*.
- Soefje, S. A. (2019). Managing the economic impact of advanced pancreatic cancer. *The American Journal of Managed Care*, 25(1), S11-S16.
- Sohal, D.P.S., Kennedy, E.B., Cinar, P., Conroy, T., Copur, M.S. Crane, C.H. Garrido-Laguna, I. Lau, M.W. Johnson, T. Krishnamurthi, S., Moravek, C., O'Reilly, E. M., Philip, P. A., Pant, S., Shah, M.A., Sahai, V., Uronis, H. E., Zaidi, N., Laheru, D. (2020). Metastatic Pancreatic Cancer: ASCO Guideline Update. *Journal of Clinical Oncology*, 38, 3217–3230. <https://doi.org/10.1200/JCO.20.01364>.
- Sokomba, E., Wambebe, C., Chowdhury, B. K., Iriah, J., Ogbeide, O. N., & Orkor, D. (1986). Preliminary Phytochemical, Pharmacological and Antibacterial Studies of the Alkaloidal Extracts of the Leaves of Synclisia-Scabrida Miers. *Journal of Ethnopharmacology*, 18(2), 173–185. [https://doi.org/10.1016/0378-8741\(86\)90029-2](https://doi.org/10.1016/0378-8741(86)90029-2).
- Soladoye, M. O., Adetayo, M. O., Chukwuma, E. C., & Adetunji, A. N. (2010). Ethnobotanical Survey of Plants Used in the Treatment of Haemorrhoids in South-Western Nigeria. *Annals of Biological Research*, 1(4), 1–15.
- Solowey, E., Lichtenstein, M., Sallon, S., Paavilainen, H., Solowey, E., & Lorberbaum-Galski, H. (2014). Evaluating medicinal plants for anticancer activity. *Scientific World Journal*, 2014, 1–12. <https://doi.org/10.1155/2014/721402>.
- Son, I. H., Chung, I. M., Lee, S. I., Yang, H. D., & Moon, H. I. (2007). Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. *Bioorganic and Medicinal Chemistry Letters*, 17, 4753–4755. <https://doi.org/10.1016/j.bmcl.2007.06.060>.
- Song, L., Ning, S., Hou, J., & Zhao, Y. (2021). Performance of protein-ligand docking with CDK4/6 inhibitors: A case study. *Mathematical Biosciences and Engineering*, 18(1), 456–470. <https://doi.org/10.3934/MBE.2021025>.

- Stahl, E. (1969). Thin-Layer Chromatography - A Laboratory Handbook. In *Springer International Student Edition* (2nd ed.). Springer-Verlag. <https://doi.org/DOI 10.1007/978-3-642-88488-7>.
- Stewart, B.W., & Wild, C. (2014). World Cancer Report 2014. *WHO Press*.
- Sumitra C. & Krunal N. (2013). In vitro models for antioxidant activity evaluation and some medicinal plants possessing antioxidant properties : An overview. *In Vitro and in Vivo Methods for Anticancer Activity Evaluation and Some Indian Medicinal Plants Possessing Anticancer Properties: An Overview*, 2(2), 140–152.
- Sun, L., Lin, S., Zhao, R., Yu, B., Yuan, S., & Zhang, L. (2010). The saponin monomer of dwarf lilyturf tuber, DT-13, reduces human breast cancer cell adhesion and migration during hypoxia via regulation of tissue factor. *Biological & Pharmaceutical Bulletin*, 33(7), 1192–1198. <https://doi.org/10.1248/bpb.33.1192>.
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>.
- Maitra, S., Seal, T., Mallik, S., Khasnobi, A., Nandi, R. P., Vedasiromoni, J. R., & Mukherjee, B. (2003). Some pharmacological studies with Cycleanine, a diphenylbisbenzylisoquinoline alkaloid from *Stephania hernandifolia*. *Oriental Pharmacy and Experimental Medicine*, 3(3), 123–128. <https://doi.org/DOI: 10.3742/opem.2003.3.3.123>.
- Sutanto, F., Konstantinidou, M., & Dömling, A. (2020). Covalent inhibitors: A rational approach to drug discovery. *RSC Medicinal Chemistry*, 11, 876-884. <https://doi.org/10.1039/d0md00154f>.
- Takamatsu, S., Galal, A. M., Ross, S. A., Ferreira, D., ElSohly, M. A., Ibrahim, A. R. S., & El-Feraly, F. S. (2003). Antioxidant effect of flavonoids on DCF production in HL-60 cells. *Phytotherapy Research*, 17(8), 963–966. <https://doi.org/10.1002/ptr.1289>.
- Tamura, M. (1993). In *Flowering Plants—Dicotyledons: Magnoliid, Hamamelid and Caryophyllid Families* (E. Kubitzki, K., Rohwer, J. G., Bittrich, V. (ed.)). Springer: Berlin, Heidelberg. <https://doi.org/10.2471/BLT.15.164384>.
- Thomsen, N. D., Koerber, J. T., & Wells, J. A. (2013). Structural snapshots reveal distinct mechanisms of procaspase-3 and -7 activation. *Proceedings of the National Academy of Sciences of the United States of America*, 110, 8477–8482. <https://doi.org/10.1073/pnas.1306759110>.
- Tiwari, P., Kumar, B., Mandeep, K., Kaur, G., & Kaur, H. (2011). Phytochemical screening and Extraction: A Review. *Internationale Pharmaceutica Sciencia*, 1(1), 98-106.

- Uche, F. I., Drijfhout, F. P., McCullagh, J., Richardson, A., & Li, W. W. (2016). Cytotoxicity Effects and Apoptosis Induction by Bisbenzylisoquinoline Alkaloids from Triclisia subcordata. *Phytotherapy Research*, 30, 1533–1539. <https://doi.org/10.1002/ptr.5660>.
- Uche, F. I., Abed, M. N., Abdullah, M. I., Drijfhout, F. P., McCullagh, J., Claridge, T. W. D., Richardson, A., & Li, W. W. (2017). Isochondodendrine and 2'-norcocculine: Additional alkaloids from Triclisia subcordata induce cytotoxicity and apoptosis in ovarian cancer cell lines. *RSC Advances*, 7(70), 44154–44161. <https://doi.org/10.1039/c7ra08032h>.
- Uche, F. I., Guo, X., Okokon, J., Ullah, I., Horrocks, P., Boateng, J., Huang, C., & Li, W. W. (2021). In vivo efficacy and metabolism of the antimalarial cycleanine and improved in vitro antiplasmodial activity of semisynthetic analogues. *Antimicrobial Agents and Chemotherapy*, 65, e01995-20. <https://doi.org/10.1128/AAC.01995-20>.
- Uche, F. I., McCullagh, J., Claridge, T. W. D., Richardson, A., & Li, W. W. (2018). Synthesis of (aminoalkyl)cycleanine analogues: cytotoxicity, cellular uptake, and apoptosis induction in ovarian cancer cells. *Bioorganic and Medicinal Chemistry Letters*, 28(9), 1652–1656. <https://doi.org/10.1016/j.bmcl.2018.03.038>.
- Uchendu, O. J. (2020). Cancer Incidence in Nigeria: A Tertiary Hospital Experience. *Asian Pacific Journal of Cancer Care*, 5 (1), 27–32. <https://doi.org/10.31557/apjcc.2020.5.1.27-32>.
- Ujang, Z. B., Subramaniam, T., Diah, M. M., Wahid, H. B., Abdullah, B. B., Rashid, A. H. B. A., & Appleton, D. (2013). Bioguided Fractionation and Purification of Natural Bioactives Obtained from Alpinia conchigera Water Extract with Melanin Inhibition Activity. *Journal of Biomaterials and Nanobiotechnology*, 4, 265–272. <https://doi.org/10.4236/jbnb.2013.43033>.
- Urueña, C., Cifuentes, C., Castañeda, D., Arango, A., Kaur, P., Asea, A., & Fiorentino, S. (2008). Petiveria alliacea extracts uses multiple mechanisms to inhibit growth of human and mouse tumoral cells. *BMC Complementary and Alternative Medicine*, 8, 60. <https://doi.org/10.1186/1472-6882-8-60>.
- Vagia, E., Mahalingam, D., & Cristofanilli, M. (2020). The Landscape of Targeted Therapies in TNBC. *Cancers*, 12(4), 916. <https://doi.org/10.3390/cancers12040916>.
- Van Der Jeught, K., Xu, H. C., Li, Y. J., Lu, X. Bin, & Ji, G. (2018). Drug resistance and new therapies in colorectal cancer. *World Journal of Gastroenterology* 24(34), 3834–3848. <https://doi.org/10.3748/wjg.v24.i34.3834>.
- Vasconcelos Leitão da-Cunha, E., Gray, A. I. (2000). The Alkaloids. In E. Barbosa-Filho, J. M., Cordel, G.A. (Eds.), *Alkaloids: Chemistry and Biology*, 54. Academic Press: New York.

- Velec, H. F. G., Gohlke, H., & Klebe, G. (2005). DrugScoreCSD-knowledge-based scoring function derived from small molecule crystal data with superior recognition rate of near-native ligand poses and better affinity prediction. *Journal of Medicinal Chemistry*, 48, 6296–6303. <https://doi.org/10.1021/jm050436v>.
- Visconti, R., Monica, R. D., & Grieco, D. (2016). Cell cycle checkpoint in cancer: A therapeutically targetable double-edged sword. *Journal of Experimental and Clinical Cancer Research*, 35(1), 153. <https://doi.org/10.1186/s13046-016-0433-9>.
- Wambebe, C. and Ogbeide, O. N. (1982). Cycleanine. *Drugs of the Future*, 7(7), 467–468.
- Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general Amber force field. *Journal of Computational Chemistry*, 25(9), 1157–1174. <https://doi.org/10.1002/jcc.20035>.
- Wang, Q., Li, H., Tao, P., Wang, Y. P., Yuan, P., Yang, C. X., Li, J. Y., Yang, F., Lee, H., & Huang, Y. (2011). Soy isoflavones, CYP1A1, CYP1B1, and COMT polymorphisms, and breast cancer: A case-control study in southwestern China. *DNA and Cell Biology*, 30(8), 585–595. <https://doi.org/10.1089/dna.2010.1195>.
- Wang, X., Deng, K., Wang, C., Li, Y., Wang, T., Huang, Z., Ma, Y., Sun, P., Shi, Y., Yang, S., Fan, Y., & Xiang, R. (2020). Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 35(1), 414–423. <https://doi.org/10.1080/14756366.2019.1705290>.
- Wang, X., Hang, Y., Liu, J., Hou, Y., Wang, N., & Wang, M. (2017). Anticancer effect of curcumin inhibits cell growth through miR-21/PTEN/Akt pathway in breast cancer cell. *Oncology Letters*, 13(6), 4825–4831. <https://doi.org/10.3892/ol.2017.6053>.
- Waziri, P. M., Abdullah, R., Yeap, S. K., Omar, A. R., Kassim, N. K., Malami, I., How, C. W., Etti, I. C., & Abu, M. L. (2016). Clausenidin induces caspase-dependent apoptosis in colon cancer. *BMC Complementary and Alternative Medicine*, 16, 256. <https://doi.org/10.1186/s12906-016-1247-1>.
- Weaver, B. A. (2014). How Taxol/paclitaxel kills cancer cells. *Molecular Biology of the Cell*, 25, 2677–2681. <https://doi.org/10.1091/mbc.E14-04-0916>.
- Weckerle, C. S., de Boer, H. J., Puri, R. K., van Andel, T., Bussmann, R. W., & Leonti, M. (2017). Recommended standards for conducting and reporting ethnopharmacological field studies. *Journal of Ethnopharmacology*, 210, 125–132. <https://doi.org/10.1016/j.jep.2017.08.018>.
- Wei, C., Pan, Y., Huang, H., & Li, Y. P. (2018). Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31 levels. *European Review for Medical and Pharmacological Sciences*, 22(1), 40–45.

<https://doi.org/10.26355/eurrev-201801-14098>.

- Wei, Y., Xu, Y., Han, X., Qi, Y., Xu, L., Xu, Y., Yin, L., Sun, H., Liu, K., & Peng, J. (2013). Anti-cancer effects of dioscin on three kinds of human lung cancer cell lines through inducing DNA damage and activating mitochondrial signal pathway. *Food and Chemical Toxicology*, 59, 118–128. <https://doi.org/10.1016/j.fct.2013.05.054>.
- Whitacre, C. M., Zborowska, E., Willson, J. K., Berger, N. A. (1999). Detection of poly (ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. *Clinical Cancer Research*, 5(3), 665-672.
- Wink, M. (2015). Modes of Action of Herbal Medicines and Plant Secondary Metabolites. *Medicines*, 22, 251–286. <https://doi.org/10.3390/medicines2030251>.
- Wirtz, A. (2013). Ultra-High Performance Liquid Chromatography and Its Applications. *Journal of Separation Science*, (Quanyun, A. Ed.). John Wiley & Sons, Inc. <https://doi.org/10.1002/jssc.201470014>.
- Woo, H. D., Lee, J., Choi, I. J., Kim, C. G., Lee, J. Y., Kwon, O., & Kim, J. (2014). Dietary flavonoids and gastric cancer risk in a Korean population. *Nutrients*, 6(11), 4961–4973. <https://doi.org/10.3390/nu6114961>.
- Woods, K. W., Fischer, J. P., Claiborne, A., Li, T., Thomas, S. A., Zhu, G. D., Diebold, R. B., Liu, X., Shi, Y., Klinghofer, V., Han, E. K., Guan, R., Magnone, S. R., Johnson, E. F., Bouska, J. J., Olson, A. M., Jong, R. de, Oltersdorf, T., Luo, Y., ... Li, Q. (2006). Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. *Bioorganic and Medicinal Chemistry*, 14, 6832–6846. <https://doi.org/10.1016/j.bmc.2006.06.047>.
- World Health Organization. (2018). *WHO / Cancer. Fact sheet February 2018*. WHO. <https://doi.org/10.1016/j.tetlet.2006.03.195>.
- World Health Organization. (2020). Globocan 2020. *International Agency for Research*.
- Wright, G. D. (2017). Opportunities for natural products in 21st century antibiotic discovery. *Natural Product Reports*, 34(7), 694-701. <https://doi.org/10.1039/c7np00019g>.
- Wu, P. K., Becker, A., & Park, J. I. (2020). Growth inhibitory signaling of the raf/mek/erk pathway. *International Journal of Molecular Sciences*, 21(15), 5436. <https://doi.org/10.3390/ijms21155436>. www.mcf7.com, April 2013
- Xie, Y. H., Chen, Y. X., & Fang, J. Y. (2020). Comprehensive review of targeted therapy for colorectal cancer. *Signal Transduction and Targeted Therapy* 5, 22. <https://doi.org/10.1038/s41392-020-0116-z>.
- Xu, F., Na, L., Li, Y., & Chen, L. (2020). Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. *Cell and Bioscience*, 10

54. <https://doi.org/10.1186/s13578-020-00416-0>.
- Xu, F. X., Yuan, C., Wan, J. B., Yan, R., Hu, H., Li, S. P., & Zhang, Q. W. (2015). A novel strategy for rapid quantification of 20(S)-protopanaxatriol and 20(S)-protopanaxadiol saponins in *Panax notoginseng* P. ginseng and *P. quinquefolium*. *Natural Product Research*, 29(1), 46-52. <https://doi.org/10.1080/14786419.2014.957698>.
- Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017). Recent advances of highly selective CDK4/6 inhibitors in breast cancer. *Journal of Hematology and Oncology*, 10, 97. <https://doi.org/10.1186/s13045-017-0467-2>.
- Xu, Z., & Deng, M. (2017). Identification and Control of Common Weeds: Volume 2. In *Archives of Health Investigation*. Springer Netherlands. <https://doi.org/10.1007/978-94-024-1157-7>.
- Yan X-B., Xie T., Wang S. D., Wang Z., Li H. Y., Ye. Z. M. (2018). Apigenin inhibits proliferation of human chondrosarcoma cells via cell cycle arrest and mitochondrial apoptosis induced by ROS generation-an in vitro and in vivo study. *International Journal of Clinical Experimental Medicine*, 11(3), 1615–1631.
- Ye, N., Chen, C.-H., Chen, T. T., Song, Z., He, J.-X., Huan, X.-J., Song, S.-S., Liu, Q., Chen, Y., Ding, J., Xu, Y., Miao, Z.-H., & Zhang, A. (2013). Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors. *Journal of Medicinal Chemistry*, 56(7), 2885–2903. <https://doi.org/http://doi.org/10.1021/jm301825t>.
- Ye, L., Jia, Y., Ji, K., Sanders, A. J., Xue, K., Ji, J., Mason, M. D., & Jiang, W. G. (2015). Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis (Review). *Oncology Letters*, 10, 1240-1250. <https://doi.org/10.3892/ol.2015.3459>.
- Yousuf, M., Khan, P., Shamsi, A., Shahbaaz, M., Hasan, G. M., Haque, Q. M. R., Christoffels, A., Islam, A., & Imtaiyaz, H. M. (2020). Inhibiting CDK6 activity by quercetin is an attractive strategy for cancer therapy. *ACS Omega*, 5(42), 27480–27491. <https://doi.org/10.1021/acsomega.0c03975>.
- Yue, Q., Gao, G., Zou, G., Yu, H., & Zheng, X. (2017). Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements. *BioMed Research International*, 2017, 8412508. <https://doi.org/10.1155/2017/8412508>.
- Yumnamcha, T., Roy, D., Devi, M. D., & Nongthomba, U. (2015). Evaluation of developmental toxicity and apoptotic induction of the aqueous extract of *Millettia pachycarpa* using zebrafish as model organism. *Toxicological and Environmental Chemistry*, 97, 1363–1381. <https://doi.org/10.1080/02772248.2015.1093750>.

- Zafar, S. Y., Peppercorn, J. M., Schrag, D., Taylor, D. H., Goetzinger, A. M., Zhong, X., & Abernethy, A. P. (2013). The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience. *The Oncologist*, 18, 381–390. <https://doi.org/10.1634/theoncologist.2012-0279>.
- Zafar, M., Sarfraz, I., Rasul, A., Jabeen, F., Samiullah, K., Hussain, G., Riaz A., & Ali M. (2018). Tubeimoside-1, Triterpenoid Saponin, as a Potential Natural Cancer Killer. *Natural Product Communication*, 12(0), 1-9. <https://doi.org/10.1177/1934578X1801300530>
- Zakaria, N. H., Hassan, N. I., & Wai, L. K. (2020). Molecular docking study of the interactions between plasmodium falciparum lactate dehydrogenase and 4-aminoquinoline hybrids. *Sains Malaysiana*, 49(8), 1905–1913. <https://doi.org/10.17576/jsm-2020-4908-12>.
- Zandarashvili, L., Langelier, M. F., Velagapudi, U. K., Hancock, M. A., Steffen, J. D., Billur, R., Hannan, Z. M., Wicks, A. J., Krastev, D. B., Pettitt, S. J., Lord, C. J., Talele, T. T., Pascal, J. M., & Black, B. E. (2020). Structural basis for allosteric PARP-1 retention on DNA breaks. *Science*, 368(6486), eaax6367. <https://doi.org/10.1126/science.aax6367>.
- Zarin, M. A., Wan, H. Y., Isha, A., & Armania, N. (2016). Antioxidant, antimicrobial and cytotoxic potential of condensed tannins from Leucaena leucocephala hybrid-Rendang. *Food Science and Human Wellness*, 5(2), 65–75. <https://doi.org/10.1016/j.fshw.2016.02.001>.
- Zhang, J., Zhang, L., Xu, Y., Jiang, S., & Shao, Y. (2018). Deciphering the binding behavior of flavonoids to the cyclin dependent kinase 6/ cyclin D complex. *PLoS ONE*, 13(5), e01. <https://doi.org/10.1371/journal.pone.0196651>.
- Zhang, W., Yang, S., Liu, J., Bao, L., Lu, H., Li, H., Pan, W., Jiao, Y., He, Z., & Liu, J. (2019). Screening antiproliferative drug for breast cancer from bisbenzylisoquinoline alkaloid tetrandrine and fangchinoline derivatives by targeting BLM helicase. *BMC Cancer*, 19, 1009. <https://doi.org/10.1186/s12885-019-6146-7>.
- Zhang, W., Chen, G., & Deng, C. Q. (2012). Effects and mechanisms of total Panax notoginseng saponins on proliferation of vascular smooth muscle cells with plasma pharmacology method. *Journal of Pharmacy and Pharmacology*, 64(1), 139–145. <https://doi.org/10.1111/j.2042-7158.2011.01379.x>.
- Zhang, W., Su, J., Xu, H., Yu, S., Liu, Y., Zhang, Y., Sun, L., Yue, Y., & Zhou, X. (2017). Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells. *PLoS ONE*, 12(6), e0179672. <https://doi.org/10.1371/journal.pone.0179672>.
- Zhang, Z., Wang, Y., Vikis, H. G., Johnson, L., Liu, G., Li, J., Anderson, M. W., Sills, R. C., Hong, H. L., Devereux, T. R., Jacks, T., Guan, K. L., & You, M. (2001). Wildtype Kras2 can inhibit lung carcinogenesis in mice. *Nature Genetics*, 29(1), 25–33. <https://doi.org/10.1038/ng721>.

- Zhang, M., Tian, J., Wang, R., Song, M., Zhao, R., Chen, H., Liu, K., Shim, J. H., Zhu, F., Dong, Z., & Lee, M. H. (2020). Dasatinib Inhibits Lung Cancer Cell Growth and Patient Derived Tumor Growth in Mice by Targeting LIMK1. *Frontiers in Cell and Developmental Biology*, 8, 556532. <https://doi.org/10.3389/fcell.2020.556532>.
- Zheng, G-Y., Xin, H-L., Li, B., Xu, Y-F., Yi, T-J., Yuan H. (2012). Total Saponin from Root of Actinidia Valvata Dunn Prevents the Metastasis of Human Hepatocellular Carcinoma Cells. *Chinese Journal of Integrative Medicine*, 18(3), 197-202. <https://doi.org/10.1007/s11655-012-1055-5>.
- Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, Ti., & Yang, S. (2021). Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. *Signal Transduction and Target Therapy*, 6(1), 201. <https://doi.org/10.1038/s41392-021-00572-w>.
- Zhou, X. M., Wong, B. C. Y., Fan, X. M., Zhang, H. B., Lin, M. C. M., Kung, H. F., Fan, D. M., & Lam, S. K. (2001). Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. *Carcinogenesis*, 22(9), 1393–1397.
- Zhou, Z., & Sun, M. Z. (2019). Crkii overexpression promotes the in vitro proliferation, migration and invasion potential of murine hepatocarcinoma hca-p cells. *Oncology Letters*, 17, 5169–5174. <https://doi.org/10.3892/ol.2019.10194>.
- Zhu, C., Liu, F., Qian, W., Zhang, T., & Li, F. (2016). Combined Effect of Sodium Selenite and Ginsenoside Rh2 on HCT116 Human Colorectal Carcinoma Cells. *Archives of Iranian Medicine*, 19(1), 23-29. <https://doi.org/0161901/AIM.005>.